<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Infliximab (including biosimilars): Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Infliximab (including biosimilars): Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Infliximab (including biosimilars): Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="8984" href="/d/html/8984.html" rel="external">see "Infliximab (including biosimilars): Drug information"</a> and <a class="drug drug_patient" data-topicid="10762" href="/d/html/10762.html" rel="external">see "Infliximab (including biosimilars): Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F5708921"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Serious infections:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Patients treated with infliximab are at an increased risk of developing serious infections that may lead to hospitalization or death. Most patients who developed these infections were taking concomitant immunosuppressants, such as methotrexate or corticosteroids.</p>
<p style="text-indent:-2em;margin-left:2em;">Discontinue infliximab if a patient develops a serious infection or sepsis.</p>
<p style="text-indent:-2em;margin-left:2em;">Reported infections include the following:</p>
<p style="text-indent:-2em;margin-left:6em;">Active tuberculosis (TB), including reactivation of latent TB. Patients with TB have frequently presented with disseminated or extrapulmonary disease. Patients should be tested for latent TB before infliximab use and during therapy. Treatment for latent infection should be initiated prior to infliximab use.</p>
<p style="text-indent:-2em;margin-left:6em;">Invasive fungal infections, including histoplasmosis, coccidioidomycosis, candidiasis, aspergillosis, blastomycosis, and pneumocystosis. Patients with histoplasmosis or other invasive fungal infections may present with disseminated, rather than localized, disease. Antigen and antibody testing for histoplasmosis may be negative in some patients with active infection. Empiric antifungal therapy should be considered in patients at risk of invasive fungal infections who develop severe systemic illness.</p>
<p style="text-indent:-2em;margin-left:6em;">Bacterial, viral, and other infections caused by opportunistic pathogens, including <i>Legionella</i> and <i>Listeria</i>.</p>
<p style="text-indent:-2em;margin-left:2em;">The risks and benefits of treatment with infliximab should be carefully considered prior to initiating therapy in patients with chronic or recurrent infection.</p>
<p style="text-indent:-2em;margin-left:2em;">Patients should be closely monitored for the development of signs and symptoms of infection during and after treatment with infliximab, including the possible development of TB in patients who tested negative for latent TB infection prior to initiating therapy.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Malignancy:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with tumor necrosis factor (TNF) blockers, including infliximab.</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing cases of hepatosplenic T-cell lymphoma, a rare type of T-cell lymphoma, have been reported in patients treated with TNF blockers, including infliximab. These cases have had a very aggressive disease course and have been fatal. Almost all patients had received treatment with azathioprine or 6-mercaptopurine concomitantly with a TNF-blocker at or prior to diagnosis. The majority of reported infliximab cases have occurred in patients with Crohn disease or ulcerative colitis, and most were in adolescent and young adult males.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F182756"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Avsola;</li>
<li>Inflectra;</li>
<li>Remicade;</li>
<li>Renflexis</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52867203"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Avsola;</li>
<li>Inflectra;</li>
<li>Remicade;</li>
<li>Remsima SC;</li>
<li>Renflexis</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1047891"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antirheumatic, Disease Modifying</span>;</li>
<li>
<span class="list-set-name">Gastrointestinal Agent, Miscellaneous</span>;</li>
<li>
<span class="list-set-name">Immunosuppressant Agent</span>;</li>
<li>
<span class="list-set-name">Monoclonal Antibody</span>;</li>
<li>
<span class="list-set-name">Tumor Necrosis Factor (TNF) Blocking Agent</span></li></ul></div>
<div class="block dop drugH1Div" id="F182775"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Clinical considerations:</b> The manufacturer recommends to consider premedication with antihistamines (H<sub>1</sub>-antagonist and/or H<sub>2</sub>-antagonist), acetaminophen, and/or corticosteroids to prevent and/or manage infusion-related reactions; however, efficacy of routine premedication is uncertain (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30311152','lexi-content-ref-30044357','lexi-content-ref-34300342','lexi-content-ref-31332475']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30311152','lexi-content-ref-30044357','lexi-content-ref-34300342','lexi-content-ref-31332475'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="698502f2-8371-4f7b-b52e-f26b1c2278b7">Crohn disease</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Crohn disease:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Guidelines recommend anti-tumor necrosis factor (TNF) agent use for maintenance and remission in patients with new-onset Crohn disease with high risk for complicated disease course, or in patients with active Crohn disease who do not achieve or maintain remission with an immunomodulator (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33026087']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33026087'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥3 years and Adolescents: Limited data available in ages 3 to &lt;6 years: IV: Initial: 5 mg/kg/dose at 0, 2, and 6 weeks, followed by maintenance: 5 mg/kg/dose every 8 weeks thereafter. <b>Note:</b> Therapeutic drug monitoring and dose adjustment as necessary are recommended. Patients weighing &lt;30 kg, those with extensive disease, or those with low albumin may need higher dosing (eg, 10 mg/kg/dose) and/or shorter intervals (eg, every 4 to 6 weeks) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28657923','lexi-content-ref-33384335','lexi-content-ref-33026087','lexi-content-ref-32443029','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28657923','lexi-content-ref-33384335','lexi-content-ref-33026087','lexi-content-ref-32443029','lexi-content-ref-manu.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="533fe8d7-70e8-4f2e-ab94-f98378577b58">Juvenile idiopathic arthritis; refractory to conventional disease-modifying drugs</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Juvenile idiopathic arthritis; refractory to conventional disease-modifying drugs:</b> Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥4 years and Adolescents: IV: Initial: 5 to 10 mg/kg at 0, 2, and 6 weeks; then 5 to 10 mg/kg/dose every 4 to 8 weeks thereafter, in combination with methotrexate during induction and maintenance. A wide range of doses have been reported, including doses as low as 3 mg/kg/dose and a target dose as high as 10 to 20 mg/kg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24339215','lexi-content-ref-34292215','lexi-content-ref-17763439','lexi-content-ref-20237125','lexi-content-ref-23950184','lexi-content-ref-21623000','lexi-content-ref-20822542']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24339215','lexi-content-ref-34292215','lexi-content-ref-17763439','lexi-content-ref-20237125','lexi-content-ref-23950184','lexi-content-ref-21623000','lexi-content-ref-20822542'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e2d8e162-9093-4b87-b65b-1ea65140f237">Kawasaki disease, refractory to IVIG</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Kawasaki disease, refractory to IVIG: </b>Limited data available: Infants and Children: IV: 5 to 10 mg/kg/dose as a single infusion (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28356445','lexi-content-ref-15870671','lexi-content-ref-18672254','lexi-content-ref-34715057','lexi-content-ref-21129756','lexi-content-ref-15088313','lexi-content-ref-26673981']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28356445','lexi-content-ref-15870671','lexi-content-ref-18672254','lexi-content-ref-34715057','lexi-content-ref-21129756','lexi-content-ref-15088313','lexi-content-ref-26673981'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="2409ba83-3fab-48ac-bd75-41b00b70b569">Multisystem inflammatory syndrome in children associated with SARS-CoV-2</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Multisystem inflammatory syndrome in children (MIS-C) associated with SARS-CoV-2:</b> Very limited data available: <b>Note:</b> Recommended for intensification therapy in patients who do not improve within 24 hours of initial MIS-C therapy (ie, immune globulin and methylprednisolone); do not use in patients with features of macrophage activation syndrome or in combination with anakinra (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35118829','lexi-content-ref-NIH.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35118829','lexi-content-ref-NIH.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents: IV: 5 to 10 mg/kg as a single infusion (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35118829','lexi-content-ref-34548377','lexi-content-ref-NIH.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35118829','lexi-content-ref-34548377','lexi-content-ref-NIH.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e147f438-ac03-44c7-98c9-bf0acd598ea0">Ulcerative colitis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Ulcerative colitis:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Guidelines recommend use for chronically active or steroid-dependent ulcerative colitis uncontrolled by other agents (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30044357']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30044357'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥6 years and Adolescents: IV: Initial: 5 mg/kg/dose at 0, 2, and 6 weeks, followed by maintenance: 5 mg/kg/dose every 8 weeks thereafter. <b>Note:</b> Therapeutic drug monitoring and dose adjustment as appropriate are recommended. Patients with low body weight (eg, &lt;30 kg), high BMI, high inflammatory burden, or low albumin may need higher dosing (eg, 10 mg/kg/dose) or shorter intervals (eg, every 4 weeks) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30044357','lexi-content-ref-30044358','lexi-content-ref-22516861','lexi-content-ref-32443029']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30044357','lexi-content-ref-30044358','lexi-content-ref-22516861','lexi-content-ref-32443029'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51113958"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling.</p></div>
<div class="block dohp drugH1Div" id="F51113959"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>Hepatic impairment prior to treatment initiation: </i>There are no dosage adjustments provided in the manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Hepatotoxicity during treatment: </i>Jaundice and/or marked increase in liver enzymes (≥5 times ULN): Discontinue treatment.</p></div>
<div class="block doa drugH1Div" id="F182760"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="8984" href="/d/html/8984.html" rel="external">see "Infliximab (including biosimilars): Drug information"</a>)</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosage form information: </b>Avsola (infliximab-axxq), Inflectra (infliximab-dyyb), and Renflexis (infliximab-abda) are approved as biosimilars to Remicade (infliximab). In Canada, Avsola, Inflectra, and Renflexis are also approved as biosimilars to Remicade (infliximab).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Clinical considerations:</b> Premedication with antihistamines (H<sub>1</sub>-antagonist +/- H<sub>2</sub>-antagonist), acetaminophen, and/or corticosteroids may be considered to prevent and/or manage infusion-related reactions.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="62637659-f98d-4a3f-aec5-dbd1f84dc2b2">Ankylosing spondylitis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Ankylosing spondylitis:</b>
<b>IV:</b> 5 mg/kg at 0, 2, and 6 weeks, followed by 5 mg/kg every 6 weeks thereafter.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c7f75a24-c274-4715-807f-d302e2ab342d">Colitis, immune checkpoint inhibitor-induced</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Colitis, immune checkpoint inhibitor-induced (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> For grade 2, 3, or 4 colitis with either high-risk endoscopic features on initial endoscopy examination or with persistent symptoms despite 3 days of corticosteroid therapy, consider adding infliximab to the treatment regimen (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34724392']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34724392'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 5 mg/kg at week 0, a second dose may be repeated 2 weeks later, and a third dose may be considered at 6 weeks if needed; use in combination with a corticosteroid (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34724392','lexi-content-ref-34172516']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34724392','lexi-content-ref-34172516'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="894e2a7e-3fff-4cb6-8ddb-f11aa30fb548">COVID-19, hospitalized patients</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>COVID-19, hospitalized patients (alternative agent) (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>For use in patients who are hospitalized who require oxygen (eg, high-flow oxygen, noninvasive ventilation) and those with lower but increasing oxygen requirements and evidence of systemic inflammation who cannot use preferred agents (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-NIH.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-NIH.2'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV: </b>5 mg/kg as a single dose as part of an appropriate combination regimen (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-NIH.2','lexi-content-ref-37428480']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-NIH.2','lexi-content-ref-37428480'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c67c5889-0329-4697-8e94-8d70bc250092">Crohn disease, moderate to severe, induction and maintenance of remission</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Crohn disease, moderate to severe, induction and maintenance of remission: Note:</b> Combination with an immunomodulator (ie, thiopurine or methotrexate) is generally preferred (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29610508','lexi-content-ref-34051983']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29610508','lexi-content-ref-34051983'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 5 mg/kg at 0, 2, and 6 weeks, followed by 5 mg/kg every 8 weeks thereafter; dose may be increased to 10 mg/kg every 8 weeks in patients who respond but then lose their response. If no response by week 14, consider discontinuing therapy.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4fb8c5f3-a1b3-4ba3-b517-cc8663ef3c7c">Plaque psoriasis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Plaque psoriasis: IV:</b> 5 mg/kg at 0, 2, and 6 weeks, followed by 5 mg/kg every 8 weeks thereafter. <b>Note</b>: Some patients may require 10 mg/kg and/or dosing as frequently as every 4 weeks during the maintenance phase (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30772098']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30772098'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1bfcea56-f4f1-4785-9277-8d2c90e99a99">Psoriatic arthritis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Psoriatic arthritis (with or without methotrexate): IV:</b> 5 mg/kg at 0, 2, and 6 weeks, followed by 5 mg/kg every 8 weeks thereafter.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="32df9255-b17c-4d08-8442-5a9228a555a8">Pustular psoriasis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pustular psoriasis (off-label use):</b>
<b>IV:</b> 5 mg/kg at week 0, 2, and 6, followed by 5 mg/kg every 8 weeks for up to 46 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24910924','lexi-content-ref-21544940']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24910924','lexi-content-ref-21544940'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="32775de1-c27b-4d28-84e6-04adfdee9a40">Rheumatoid arthritis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Rheumatoid arthritis: Note:</b> For use as adjunctive therapy in patients who have not met treatment goals despite maximally tolerated methotrexate therapy; may also be used off label as an alternative to methotrexate in disease-modifying antirheumatic drug–naive patients with moderate to high disease activity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34101387','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34101387','lexi-content-ref-manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b></p>
<p style="text-indent:-2em;margin-left:6em;">Induction therapy followed by IV maintenance therapy: 3 mg/kg at 0, 2, and 6 weeks.</p>
<p style="text-indent:-2em;margin-left:6em;">Induction therapy followed by SUBQ (Remsima [Canadian product]) maintenance therapy: 3 mg/kg at 0 and 2 weeks.</p>
<p style="text-indent:-2em;margin-left:6em;">Maintenance therapy: 3 mg/kg every 8 weeks thereafter; for patients who have incomplete responses, consider adjusting the dose up to 10 mg/kg every 8 weeks or treating as often as every 4 weeks, although consider the risk of serious infections is increased at higher doses or with more frequent administration.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>SUBQ:</b> Remsima (Canadian product):</p>
<p style="text-indent:-2em;margin-left:6em;">Induction therapy: 120 mg at 0, 1, 2, 3, and 4 weeks.</p>
<p style="text-indent:-2em;margin-left:6em;">Initial maintenance therapy: 120 mg once every 2 weeks; begin 2 weeks following the week 4 SUBQ dose or 4 weeks following the week 2 IV dose.</p>
<p style="text-indent:-2em;margin-left:6em;">Patients receiving IV maintenance therapy and switching to SUBQ maintenance therapy: 120 mg once every 2 weeks; administer first dose 8 weeks after the last IV infusion.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Missed doses:</i></p>
<p style="text-indent:-2em;margin-left:8em;">≤7 days: Administer missed dose immediately; administer following dose as per originally planned date and thereafter on the original biweekly schedule.</p>
<p style="text-indent:-2em;margin-left:8em;">≥8 days: Skip the missed dose and administer next dose as per the originally planned date and thereafter on the original biweekly schedule.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="45ccdfdc-12e9-4566-918e-b18caa15a979">Sarcoidosis, refractory</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Sarcoidosis, refractory (adjunctive agent) (off-label use):</b>
<b>Note:</b> For use as adjunctive therapy in patients in whom treatment goals have not been met despite glucocorticoids and other immunosuppressant therapy (eg, methotrexate); use in combination with glucocorticoids and/or methotrexate may prevent infliximab autoantibody formation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16840744','lexi-content-ref-25078637','lexi-content-ref-34140301']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16840744','lexi-content-ref-25078637','lexi-content-ref-34140301'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Initial: IV<i>: </i></b>3 to 5 mg/kg at weeks 0, 2, and 6 (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16840744','lexi-content-ref-25078637']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16840744','lexi-content-ref-25078637'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Maintenance: IV: </b>3 to 5 mg/kg every 4 to 8 weeks thereafter (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16840744','lexi-content-ref-25078637','lexi-content-ref-34140301']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16840744','lexi-content-ref-25078637','lexi-content-ref-34140301'])">Ref</a></span>). The optimal frequency and duration of therapy are not known, and must be individualized based on response; after a stable response is achieved (eg, after ≥6 to 12 months of therapy), may consider gradually prolonging the dosing interval (eg, up to every 12 weeks) or reducing the dose and discontinue if response remains adequate after although approaches vary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25078637','lexi-content-ref-34140301','lexi-content-ref-34143362','lexi-content-ref-35264154']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25078637','lexi-content-ref-34140301','lexi-content-ref-34143362','lexi-content-ref-35264154'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e147f438-ac03-44c7-98c9-bf0acd598ea0">Ulcerative colitis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Ulcerative colitis: IV:</b> 5 mg/kg at 0, 2, and 6 weeks, followed by 5 mg/kg every 8 weeks thereafter. Doses up to 10 mg/kg were studied in clinical trials with similar efficacy observed with both doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16339095']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16339095'])">Ref</a></span>); combination therapy with a thiopurine (eg, azathioprine, mercaptopurine) has shown increased efficacy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30840605','lexi-content-ref-24512909']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30840605','lexi-content-ref-24512909'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment with heart failure:</b> Weigh risk versus benefits for individual patient:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mild heart failure (NYHA class I/II): </i>No dosage adjustment necessary; use with caution and monitor closely for worsening of heart failure.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Moderate to severe (NYHA class III or IV):</i> ≤5 mg/kg.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990646"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doha drugH1Div" id="F50987846"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The hepatic dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Matt Harris, PharmD, MHS, BCPS, FAST, Jeong Park, PharmD, MS, BCTXP, FCCP, FAST, Arun Jesudian, MD, Sasan Sakiani, MD.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note: </b>Abnormal baseline liver chemistries (AST/ALT) are common in patients with autoimmune disorders and often improve with infliximab use; however, baseline LFT elevations should be investigated to ensure etiology (eg, viral hepatitis, metabolic dysfunction associated steatotic liver disease [MASLD]) has been determined and mitigated prior to initiation of infliximab treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19560226','lexi-content-ref-21122513','lexi-content-ref-29627896','lexi-content-ref-24259964','lexi-content-ref-Expert.DOH']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19560226','lexi-content-ref-21122513','lexi-content-ref-29627896','lexi-content-ref-24259964','lexi-content-ref-Expert.DOH'])">Ref</a></span>). Consider holding infliximab prior to living donor solid organ transplant (eg, hold IV infliximab for at least 4 weeks; hold SUBQ infliximab for 1 week) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35690919']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35690919'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Initial or dose titration with preexisting liver cirrhosis: </b>No dosage adjustment necessary for any degree of liver dysfunction (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34707687','lexi-content-ref-Expert.DOH']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34707687','lexi-content-ref-Expert.DOH'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Elevated liver-associated enzymes during treatment:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Infliximab-induced hepatoxicity: </i></b>
<b>Note:</b> Idiosyncratic elevation of hepatic transaminases occur in &gt;30% of patients at around 10 weeks; especially in those with elevated ALT at baseline or MASLD (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33318791','lexi-content-ref-26032391','lexi-content-ref-31643528']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33318791','lexi-content-ref-26032391','lexi-content-ref-31643528'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b></b>
<b>AST/ALT &lt;5 times ULN: </b> Continue infliximab therapy with frequent (eg, every 2 weeks) LFT monitoring; most cases (~75%) resolve without further intervention (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33318791','lexi-content-ref-25516646','lexi-content-ref-32127737']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33318791','lexi-content-ref-25516646','lexi-content-ref-32127737'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>AST/ALT </b>
<b>≥5 times ULN:</b> Discontinue infliximab therapy and consult hepatologist (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOH']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOH'])">Ref</a></span>). May be indicative of infliximab-induced autoimmune hepatitis, which may cause severe liver injury and can be fatal or lead to liver transplantation.</p></div>
<div class="block arsc drugH1Div" id="F57426427"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Autoimmune disorder</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Auto<b>antibody</b>
<b>development</b> may occur with the use of tumor necrosis factor (TNF) alpha inhibitors, including infliximab. Most frequently, autoantibodies include anti-nuclear antibody, anti–double-stranded DNA; less frequently, anti-extractable nuclear antigen, anti-histone Ab, and anti-cardiolipin Ab (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33747126','lexi-content-ref-25110258','lexi-content-ref-16439435']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33747126','lexi-content-ref-25110258','lexi-content-ref-16439435'])">Ref</a></span>). Frequency of autoantibody development varies depending on underlying disease, specific TNF alpha inhibitor medication, and the duration of use; the clinical significance of asymptomatic antibody positivity is unclear (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25110258']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25110258'])">Ref</a></span>). Antibody positivity may rarely result in the development of an autoimmune disorder, such as <b>lupus-like syndrome </b>(<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33747126','lexi-content-ref-25110258','lexi-content-ref-26768759']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33747126','lexi-content-ref-25110258','lexi-content-ref-26768759'])">Ref</a></span>). Symptoms include <b>arthralgia</b>, myalgia, mucocutaneous symptoms (eg, skin rash), cytopenia, fatigue, <b>fever</b>, serositis, and kidney injury (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33747126','lexi-content-ref-25110258']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33747126','lexi-content-ref-25110258'])">Ref</a></span>). Development of an autoimmune disorder is associated with a poor treatment response of the original disease to TNF alpha inhibitor therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33747126']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33747126'])">Ref</a></span>). It is unclear if the development of an autoimmune disorder is a true TNF alpha inhibitor class effect; several reports of rechallenge with the same TNF alpha inhibitor or a different TNF alpha inhibitor after treatment of the initial autoimmune disorder did not result in a recurrence (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25110258']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25110258'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism: </i>Unknown; postulated mechanisms include bystander activation of autoreactive lymphocytes due to drug-specific immunity, nonspecific activation of lymphocytes, direct cytotoxicity with release of autoantigens, and disruption of central T-cell tolerance (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15767026']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15767026'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied; onset of symptoms ranged from 5 weeks to 2 years post treatment (data with adalimumab) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25739794']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25739794'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Longer disease duration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33747126']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33747126'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Females (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33747126','lexi-content-ref-12851868','lexi-content-ref-24185311']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33747126','lexi-content-ref-12851868','lexi-content-ref-24185311'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Ulcerative colitis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33747126']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33747126'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Demyelinating disease</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">New-onset or exacerbation of central and peripheral nervous system <b>demyelinating disease</b>, such as <b>multiple sclerosis</b>, <b>optic neuritis</b>, acute <b>transverse myelitis</b>, <b>Guillain-Barré syndrome</b>, and <b>chronic inflammatory demyelinating polyneuropathy</b>, may occur with tumor necrosis factor (TNF) alpha inhibitor, although causality is yet to be proven (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34858738','lexi-content-ref-33370961','lexi-content-ref-33945946','lexi-content-ref-32421186','lexi-content-ref-19854301','lexi-content-ref-33863839']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34858738','lexi-content-ref-33370961','lexi-content-ref-33945946','lexi-content-ref-32421186','lexi-content-ref-19854301','lexi-content-ref-33863839'])">Ref</a></span>). Symptomatic CNS demyelination associated with TNF alpha inhibitors may be monophasic and/or clinically isolated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31845616']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31845616'])">Ref</a></span>). Partial or complete resolution may occur after discontinuation of TNF alpha inhibitors (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11762947']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11762947'])">Ref</a></span>); however, approximately one-third of TNF alpha inhibitor-associated demyelinating episodes evolve into clinically definite multiple sclerosis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30767720']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30767720'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Unknown; several mechanisms have been postulated, including the following: May trigger CNS demyelination directly by immune activation in genetically and/or immunologically predisposed individuals (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31845616']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31845616'])">Ref</a></span>); may inhibit remyelination via TNF type-2 receptor (TNFR2) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9345421']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9345421'])">Ref</a></span>); may increase ingress of auto-reactive T cells in the CNS; may alter downstream cytokine responses; may neutralize TNF systemically but not within the CNS, creating an artificially high local concentration of brain TNF (known as sponge effect); may permit latent CNS viral infection; or may promote anti-drug antibodies and immune complexes that are contributory to demyelination events (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28337644','lexi-content-ref-25169849']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28337644','lexi-content-ref-25169849'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied; mean time of exposure to TNF alpha inhibitors before onset of symptoms: 18 months; reported with infliximab after 1 dose and up to 14 years after initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31845616','lexi-content-ref-28337644','lexi-content-ref-11762947']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31845616','lexi-content-ref-28337644','lexi-content-ref-11762947'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Preexisting or recent onset central or peripheral nervous system demyelinating disorders</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Dermatologic reactions</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Various cutaneous eruptions have been reported, including <b>psoriasiform eruption</b> (either new onset or exacerbation), hidradenitis suppurativa, <b>lupus-like syndrome</b>, <b>eczematous rash</b>, <b>pustular rash</b>, <b>maculopapular rash</b>, and hypersensitivity angiitis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32895360','lexi-content-ref-26641955','lexi-content-ref-32527153','lexi-content-ref-26965410','lexi-content-ref-22515220','lexi-content-ref-17300238','lexi-content-ref-26422518','lexi-content-ref-31290151','lexi-content-ref-28854831','lexi-content-ref-17632266','lexi-content-ref-29718343','lexi-content-ref-21839501']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32895360','lexi-content-ref-26641955','lexi-content-ref-32527153','lexi-content-ref-26965410','lexi-content-ref-22515220','lexi-content-ref-17300238','lexi-content-ref-26422518','lexi-content-ref-31290151','lexi-content-ref-28854831','lexi-content-ref-17632266','lexi-content-ref-29718343','lexi-content-ref-21839501'])">Ref</a></span>). In most patients with psoriatic lesions, infliximab can be continued (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26641955','lexi-content-ref-22960136','lexi-content-ref-26195181','lexi-content-ref-34319562']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26641955','lexi-content-ref-22960136','lexi-content-ref-26195181','lexi-content-ref-34319562'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Psoriasiform eruptions: Non–dose-related; possibly related to cytokine imbalance or imbalance between tumor necrosis factor (TNF) alpha and interferon-alpha (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22515220','lexi-content-ref-34625145']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22515220','lexi-content-ref-34625145'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Psoriasiform eruptions: Delayed; mean 15.6 ± 10.7 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33151572']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33151572'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Adult females (psoriatic lesions) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32527153','lexi-content-ref-31093599']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32527153','lexi-content-ref-31093599'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Smoking (psoriatic lesions) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26235565']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26235565'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Males (palmoplantar pustulosis)</p>
<p style="text-indent:-2em;margin-left:6em;">• Younger patients (&lt;40 years) (palmoplantar pustulosis) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29869804']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29869804'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Patients with inflammatory bowel disease compared to other inflammatory diseases (psoriasiform reactions more frequent and severe) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28218339']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28218339'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Females (hidradenitis suppurativa) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31290151']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31290151'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Cross-reactivity data among TNF alpha inhibitors in patients who develop psoriatic lesions are conflicting (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33151572','lexi-content-ref-34402108','lexi-content-ref-28211161','lexi-content-ref-30028008','lexi-content-ref-34625145']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33151572','lexi-content-ref-34402108','lexi-content-ref-28211161','lexi-content-ref-30028008','lexi-content-ref-34625145'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Heart failure</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">New-onset <b>heart failure</b> (HF) and <b>worsening of heart failure</b> have been reported with tumor necrosis factor (TNF) alpha inhibitors, including infliximab; however, data are conflicting, and risk is unclear (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21328309']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21328309'])">Ref</a></span>). Rheumatoid arthritis (RA) may be a risk factor for HF development (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15692992']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15692992'])">Ref</a></span>). Some data suggest that TNF alpha inhibitors may reduce the risk of HF in the RA population by improving inflammation, lowering disease activity, and improving surrogate markers of cardiovascular disease (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20038753','lexi-content-ref-34496051','lexi-content-ref-20472597']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20038753','lexi-content-ref-34496051','lexi-content-ref-20472597'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Dose-related, not clearly established; postulated mechanisms include pro-inflammatory cytokine activation, accelerated atherosclerosis, and reduced physical activity related to the underlying rheumatologic disease (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24093840','lexi-content-ref-16981296']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24093840','lexi-content-ref-16981296'])">Ref</a></span>). “Reverse-signaling” may occur, leading to cardiotoxic effects; TNF on cardiomyocytes of the failing heart may act as receptors, activating intracellular signaling pathways, potentiating the toxic effect of the cytokine (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10843670','lexi-content-ref-23557269','lexi-content-ref-29895751']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10843670','lexi-content-ref-23557269','lexi-content-ref-29895751'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied; median 8.5 months (range: 5 to 17 months) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Kwon.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Kwon.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Higher doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12796126']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12796126'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Preexisting left ventricular dysfunction or HF</p>
<p style="text-indent:-2em;margin-left:6em;">• Higher disease activity (inflammation) (eg, disease activity score [DAS28], C-reactive protein, erythrocyte sedimentation rate) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24458537','lexi-content-ref-21216812','lexi-content-ref-25609412','lexi-content-ref-25776112']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24458537','lexi-content-ref-21216812','lexi-content-ref-25609412','lexi-content-ref-25776112'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hepatitis B virus reactivation</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Reactivation of hepatitis B virus (HBV) may occur with immunosuppressive or biologic therapy, including tumor necrosis factor (TNF) alpha inhibitors (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28219691']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28219691'])">Ref</a></span>). <b>Reactivation of HBV</b> may occur in both patients who are HBsAg-positive and in patients who are HBsAg-negative/HBcAb-positive with detectable HBV DNA (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21719446']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21719446'])">Ref</a></span>). Criteria for HBV reactivation includes (1) a rise in HBV DNA compared to baseline (or an absolute level of HBV DNA when a baseline is unavailable) and (2) reverse seroconversion (seroreversion) from HBsAg-negative to HBsAg-positive for patients who are HBsAg-negative and anti-HBc–positive (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29405329']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29405329'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Inhibits stimulation of HBV-specific T lymphocytes, promoting HBV reactivation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21719446']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21719446'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied; 2 weeks after initiation, up to a year after discontinuation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28219691']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28219691'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Males (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34427860','lexi-content-ref-28219691']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34427860','lexi-content-ref-28219691'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Older age (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34427860','lexi-content-ref-28219691']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34427860','lexi-content-ref-28219691'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Presence of cirrhosis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34427860','lexi-content-ref-28219691']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34427860','lexi-content-ref-28219691'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• High baseline HBV DNA level (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34427860','lexi-content-ref-28219691']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34427860','lexi-content-ref-28219691'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• HBeAg or HBsAg seropositivity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34427860','lexi-content-ref-28219691']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34427860','lexi-content-ref-28219691'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Absence of anti-HBs among patients with resolved HBV infection (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34427860']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34427860'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Chronic HBV (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28219691']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28219691'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Non-A HBV genotype (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28219691']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28219691'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Hepatitis C, hepatitis D, or HIV co-infection (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28219691']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28219691'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hepatoxicity</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Infliximab has been associated with <b>increased serum transaminases </b>and <b>hepatotoxicity </b>(<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32025603']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32025603'])">Ref</a></span>). <b>Acute</b>
<b>hepatic failure</b>, <b>cholestatic hepatitis</b> (including vanishing bile duct syndrome), <b>reactivation of</b>
<b>hepatitis B</b> (<b>HBV</b>), and <b>autoimmune hepatitis </b>have been reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30637218','lexi-content-ref-35273881','lexi-content-ref-23333219','lexi-content-ref-29564668','lexi-content-ref-26140007','lexi-content-ref-32025603']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30637218','lexi-content-ref-35273881','lexi-content-ref-23333219','lexi-content-ref-29564668','lexi-content-ref-26140007','lexi-content-ref-32025603'])">Ref</a></span>). Elevated aminotransferases between 2 to 3 times the upper limit of normal may occur that are usually transient and asymptomatic (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25756190']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25756190'])">Ref</a></span>); although, may not always improve after discontinuation of infliximab (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32025603']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32025603'])">Ref</a></span>). Resolution of symptoms in patients who develop an autoimmune hepatitis may require initiation of corticosteroid therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34487751','lexi-content-ref-23333219']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34487751','lexi-content-ref-23333219'])">Ref</a></span>). Immunomodulatory use, in particular methotrexate, may decrease the risk of hepatotoxicity associated with tumor necrosis factor (TNF) alpha inhibitors (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25131534']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25131534'])">Ref</a></span>). Patients often tolerate a different TNF alpha inhibitor (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25131534','lexi-content-ref-34487751','lexi-content-ref-19370307','lexi-content-ref-16550301','lexi-content-ref-24707412']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25131534','lexi-content-ref-34487751','lexi-content-ref-19370307','lexi-content-ref-16550301','lexi-content-ref-24707412'])">Ref</a></span>); although, hepatotoxicity may recur with an alternative agent in some cases (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26692395']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26692395'])">Ref</a></span>). Hepatotoxicity is more commonly associated with infliximab, compared to adalimumab and other TNF alpha inhibitors (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25131534','lexi-content-ref-28652663']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25131534','lexi-content-ref-28652663'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Unknown; idiosyncratic drug reaction (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29564668']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29564668'])">Ref</a></span>) or autoimmunity due to development of autoantibodies (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23333219']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23333219'])">Ref</a></span>). A hepatocellular pattern of injury is often observed along with induction of antiantibodies (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34487751','lexi-content-ref-26692395','lexi-content-ref-32025603']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34487751','lexi-content-ref-26692395','lexi-content-ref-32025603'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied; elevated aminotransferases usually occur after 2 to 5 infusions (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32025603']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32025603'])">Ref</a></span>). Duration of therapy prior to hepatotoxicity ranges from 3 days to more than 1 year (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32025603']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32025603'])">Ref</a></span>), with a median duration of approximately 3 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34487751','lexi-content-ref-23333219']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34487751','lexi-content-ref-23333219'])">Ref</a></span>). Autoimmune hepatitis has a longer latency period than nonimmune cases (16 weeks vs 10 weeks, respectively) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23333219']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23333219'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Abnormal baseline liver biochemistry (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32127737']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32127737'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Preexisting liver disease (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32127737']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32127737'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Male sex (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32127737']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32127737'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Infection</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Tumor necrosis factor (TNF) alpha inhibitors may be associated with <b>infection</b> (including <b>serious infection</b>). In clinical trials, serious infections were numerically higher among patients treated with TNF alpha inhibitors than among patients who received placebo. Meta-analyses and observational studies have reported inconsistency in risk. One study reported an increase in serious infection in patients treated with TNF alpha inhibitors (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16705109']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16705109'])">Ref</a></span>). Another study found no increase in risk (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18753157']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18753157'])">Ref</a></span>). An observational study did not demonstrate an increased infection risk among patients receiving TNF alpha inhibitor versus comparators (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22056398']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22056398'])">Ref</a></span>). Infections may present as disseminated (rather than local) disease. <b>Tuberculosis disease</b> (including reactivation of tuberculosis infection), invasive <b>fungal infection</b> (including aspergillosis, blastomycosis, candidiasis, coccidioidomycosis, histoplasmosis, and pneumocystosis), and <b>bacterial infection</b>, <b>viral infection</b>, or other <b>opportunistic infection</b> (including legionellosis and listeriosis) have been reported.</p>
<p style="text-indent:-2em;margin-left:2em;">One study reported an increased infection risk in patients receiving infliximab compared to other TNF alpha inhibitors (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21328309']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21328309'])">Ref</a></span>). Another study reported a significantly increased risk of serious infection with infliximab compared with etanercept and adalimumab (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22056398']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22056398'])">Ref</a></span>). Higher infection risk with infliximab was also observed in several other studies (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18050253','lexi-content-ref-21358439','lexi-content-ref-16255017','lexi-content-ref-24608404']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18050253','lexi-content-ref-21358439','lexi-content-ref-16255017','lexi-content-ref-24608404'])">Ref</a></span>). A meta-analysis of observational studies in the inflammatory bowel disease population reported that infliximab-based therapy was associated with a lower risk of serious infections compared with adalimumab-based therapy in patients with ulcerative colitis but not Crohn disease (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30876964']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30876964'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Dose-related; TNF alpha is important in the immune response against infections, suggesting that medications that inhibit TNF alpha may increase the risk of infections (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21328309']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21328309'])">Ref</a></span>). Increased risk with infliximab may be related to large induction doses routinely given in the first 6 weeks of therapy and possibly more complex biologic mechanisms, such as the ability to bind transmembrane TNF (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18050253']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18050253'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Higher doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18753157']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18753157'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Older age (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21791449']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21791449'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Chronic lung or kidney disease (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21791449']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21791449'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent immunosuppressants (eg, corticosteroids, methotrexate) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22056398','lexi-content-ref-30876964','lexi-content-ref-21791449','lexi-content-ref-16447241']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22056398','lexi-content-ref-30876964','lexi-content-ref-21791449','lexi-content-ref-16447241'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• History of an opportunistic infection</p>
<p style="text-indent:-2em;margin-left:6em;">• Chronic or recurrent infection</p>
<p style="text-indent:-2em;margin-left:6em;">• Conditions that predispose to infections (eg, advanced or poorly controlled diabetes)</p>
<p style="text-indent:-2em;margin-left:6em;">• Residence/travel in areas of endemic tuberculosis or mycoses (blastomycosis, coccidioidomycosis, histoplasmosis)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Infusion-related reactions</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Infliximab is associated with a variety of <b>hypersensitivity reactions</b>, including immediate (eg, <b>infusion-related reactions</b>) and delayed (eg, <b>serum sickness</b>-like reaction [SSLR], <b>maculopapular rash</b>) reactions in adult and pediatric patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16434333','lexi-content-ref-20848473','lexi-content-ref-26092578']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16434333','lexi-content-ref-20848473','lexi-content-ref-26092578'])">Ref</a></span>). Immediate infusion reactions include <b>pruritus</b>, <b>flushing</b>, <b>dyspnea</b>, <b>chest discomfort</b>, <b>hypertension</b>, myalgia, <b>nausea</b>, urticaria, <b>headache</b>, <b>skin rash</b>, and <b>dizziness </b>(<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26092578']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26092578'])">Ref</a></span>). Cardiovascular and cerebrovascular reactions, as well as <b>temporary</b>
<b>vision loss</b>, have been reported during and following infusion (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16371767','lexi-content-ref-17036404','lexi-content-ref-15316423']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16371767','lexi-content-ref-17036404','lexi-content-ref-15316423'])">Ref</a></span>). Concurrent immunomodulators (eg, thiopurine, methotrexate) may reduce the risk of immediate infusion reactions (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26092578','lexi-content-ref-21162650','lexi-content-ref-24280879']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26092578','lexi-content-ref-21162650','lexi-content-ref-24280879'])">Ref</a></span>). Cross-reactivity between tumor necrosis factor alpha inhibitors is not well described. Adalimumab has been tolerated in patients with previous infusion reactions following infliximab (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21535447']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21535447'])">Ref</a></span>). In contrast, there are reports of immediate hypersensitivity reactions with adalimumab in patients who had previous infliximab-related reactions (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28110056']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28110056'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Immediate infusion reactions: Unknown; possibly related to release of cytokines, complement activation, degranulation of mast cells and basophils, or IgE or IgG mediated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26181108','lexi-content-ref-26092578','lexi-content-ref-28110056']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26181108','lexi-content-ref-26092578','lexi-content-ref-28110056'])">Ref</a></span>). Delayed hypersensitivity reactions: Non–dose-related, immunologic; delayed hypersensitivity reactions including maculopapular eruptions are T-cell mediated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26339470','lexi-content-ref-21839501']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26339470','lexi-content-ref-21839501'])">Ref</a></span>). Serum sickness-like reactions: Non–dose-related, non-immunologic or immunologic; activation of complement resulting in local and systemic inflammatory responses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26092578']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26092578'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Immediate infusion reactions: Rapid; during the infusion or within 1 to 2 hours of completion (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26092578']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26092578'])">Ref</a></span>). Infusion reactions occur most commonly during the third and fourth infusion (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21162650']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21162650'])">Ref</a></span>); although may occur with the first infusion (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22589260']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22589260'])">Ref</a></span>). Delayed infusion reactions: Varied; develop &gt;24 hours post infusion, with a mean of 7.2 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22589260']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22589260'])">Ref</a></span>). Serum sickness-like reaction: Varied; develops 1 to 3 weeks following initiation; in patients who have been previously sensitized, reactions can occur as early as 24 to 36 hours following infusion (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26092578']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26092578'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Development of antibodies to infliximab increases the risk for acute infusion reactions but not delayed reactions (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21162650','lexi-content-ref-24280879']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21162650','lexi-content-ref-24280879'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Episodic administration and resumption of infliximab infusions after a prolonged drug-free interval (&gt;12 weeks) increases risk of late infusion reactions to infliximab (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26092578','lexi-content-ref-21162650','lexi-content-ref-21535447']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26092578','lexi-content-ref-21162650','lexi-content-ref-21535447'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Females, immunosuppressive use for &lt;4 months, and prior infusion reactions are risk factors for subsequent infusion reactions in children (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12492735']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12492735'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Malignancy</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Lymphoma and other malignancies (may be fatal) have been reported in children and adolescents receiving tumor necrosis factor (TNF) alpha inhibitors, including infliximab. Half the cases are lymphomas (<b>Hodgkin lymphoma</b> and <b>non-Hodgkin lymphoma</b>), while other cases varied and included rare malignancies usually associated with immunosuppression and malignancies not typically observed in this population. Most patients were receiving concomitant immunosuppressants. <b>Hepatosplenic T-cell lymphoma</b>, a rare T-cell lymphoma, has been reported (some fatal) primarily in patients with Crohn disease or ulcerative colitis treated with adalimumab and who received concomitant azathioprine or mercaptopurine; reports occurred predominantly in adolescent and young adult males. <b>Malignant melanoma</b> and <b>Merkel cell carcinoma</b> have been reported. Females with rheumatoid arthritis (RA) had a higher incidence of invasive cervical cancer.</p>
<p style="text-indent:-2em;margin-left:2em;">Long-term observational studies and meta-analyses indicate no association between TNF alpha inhibitor therapy and an overall increased risk of cancer (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15829572','lexi-content-ref-30289537']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15829572','lexi-content-ref-30289537'])">Ref</a></span>). One study reported a significant increase in lymphomas in patients with RA receiving TNF alpha inhibitors compared to the general population. However, there was no significant increased risk of lymphomas in patients receiving TNF alpha inhibitors compared to those receiving conventional synthetic DMARDs or with dose, increasing time since initiation, or cumulative duration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18467516']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18467516'])">Ref</a></span>). Another study reported no difference in the risk of solid tumors in patients with RA receiving TNF alpha inhibitors compared to those receiving conventional synthetic DMARDs (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24685910']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24685910'])">Ref</a></span>). Other studies reported no increased risk of malignancy recurrence in patients receiving TNF alpha inhibitors (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25107559','lexi-content-ref-20064207']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25107559','lexi-content-ref-20064207'])">Ref</a></span>). There was no statistically significant difference in lymphoma with infliximab compared to other TNF alpha inhibitors, and cancer-related mortality was comparable to adalimumab and etanercept (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18467516','lexi-content-ref-22886739']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18467516','lexi-content-ref-22886739'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> May contribute to pro-tumor activity and suppress the anti-tumor response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29593717']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29593717'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Delayed; median 30 months (range: 1 to 84 months).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• History of COPD</p>
<p style="text-indent:-2em;margin-left:6em;">• Older age (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33604964']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33604964'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Psoriasis patients with a history of phototherapy (nonmelanoma skin cancers)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Tuberculosis</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Adult and pediatric patients treated with tumor necrosis factor (TNF) alpha inhibitors are at risk for developing <b>tuberculosis</b> (TB) <b>disease</b> (including <b>reactivated tuberculosis</b>) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31731980']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31731980'])">Ref</a></span>). A meta-analysis of randomized controlled trials (RCTs) of TNF alpha inhibitors vs control and registry/longitudinal cohort studies of TNF alpha inhibitors vs other DMARDs found a significant increase in TB risk in patients with rheumatoid arthritis (RA) treated with a TNF alpha inhibitor. In the non-RCTs, incidence rates with infliximab were higher than etanercept. Preventive treatment for TB infection reduced TB risk (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26472414']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26472414'])">Ref</a></span>). In the RCTs, no difference in TB rates were found; however, the failure to detect a difference in TB rates between the two groups may be due to a short observational period (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26472414']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26472414'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> TNF alpha inhibitors interfere with TNF alpha induction of the granuloma, which is a crucial defense mechanism in controlling TB (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31731980']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31731980'])">Ref</a></span>). TNF alpha inhibitors modulate T-cell number, function, and cytokine signaling, important for the control of TB infection (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31731980','lexi-content-ref-9826720']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31731980','lexi-content-ref-9826720'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied; median 3 to ~40 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31731980']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31731980'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Residence in an area with high TB prevalence (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31731980']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31731980'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Known TB exposure or ongoing risk factors for TB exposure (eg, travel to areas with high TB prevalence; residence in correctional facilities, long-term care facilities, or homeless shelters; certain healthcare workers) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10881762']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10881762'])">Ref</a></span>)</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F182730"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse reactions reported in adults and pediatric patients.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (12% to 26%), nausea (21%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Anemia (≤11%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum alanine aminotransferase (&lt;3 × ULN: 17% to 51%; ≥3 × ULN: 2% to 10%; ≥5 × ULN: 1% to 4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Infusion-related reaction (≤20%; severe infusion-related reaction: ≤4%)<span class="lexi-table-link-container"> (<a aria-label="Infusion-Related Reaction table link" class="lexi-table-link" data-table-id="lexi-content-infusion-related-reaction" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-infusion-related-reaction')">table 1</a>)</span><span class="table-link" style="display:none;">Infusion-Related Reaction</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Infusion-Related Reaction" frame="border" id="lexi-content-infusion-related-reaction" rules="all">
<caption style="text-align:center;">
<b>Infliximab: Adverse Reaction: Infusion-Related Reaction</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Infliximab)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Infliximab)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Comments</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">18%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Children and adolescents</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Ulcerative colitis</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">22</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Maintenance therapy</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">18%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Children and adolescents</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Crohn disease</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">112</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">13%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Children and adolescents</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Ulcerative colitis</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">60</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Severe: 4%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Moderate to severe psoriasis</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">219</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Re-treatment induction therapy</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Severe: &lt;1%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Moderate to severe psoriasis</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">222</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Maintenance therapy</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">18%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Pooled clinical data</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">~20%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">~10%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Pooled clinical data</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Severe: &lt;1%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Pooled clinical data</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Immunologic: Antibody development (10% to 52%), positive ANA titer (~50%)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Abscess (≤15%), infection (27% to 74%; including serious infection)<span class="lexi-table-link-container"> (<a aria-label="Infection table link" class="lexi-table-link" data-table-id="lexi-content-infection" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-infection')">table 2</a>)</span><span class="table-link" style="display:none;">Infection</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Infection" frame="border" id="lexi-content-infection" rules="all">
<caption style="text-align:center;">
<b>Infliximab: Adverse Reaction: Infection</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Infliximab)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Infliximab)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Comments</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">56%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Children and adolescents</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">5 mg/kg every 8 or 12 weeks</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Crohn disease</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">112</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">59%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Children and adolescents</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">5 mg/kg every 8-week infusion</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Ulcerative colitis</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">22</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Maintenance therapy</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">52%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Children and adolescents</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">5 mg/kg every 8-week infusion</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Ulcerative colitis</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">60</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">74%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Children and adolescents</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">5 mg/kg every 8-week infusion</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Crohn disease</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">52</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">38%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Children and adolescents</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">5 mg/kg every 12-week infusion</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Crohn disease</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">51</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">50%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">5 mg/kg or 10 mg/kg every 8 weeks</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Crohn disease</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">545</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Maintenance therapy</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">27%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">18%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Ulcerative colitis</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Pooled clinical data</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">36%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">25%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Pooled clinical data</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Headache (18%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Cough (12%), pharyngitis (8% to 12%), sinusitis (14%), upper respiratory tract infection (12% to 32%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Bradycardia, edema, flushing (9%), hypertension (7%)<span class="lexi-table-link-container"> (<a aria-label="Hypertension table link" class="lexi-table-link" data-table-id="lexi-content-hypertension" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-hypertension')">table 3</a>)</span><span class="table-link" style="display:none;">Hypertension</span>, hypotension, thrombophlebitis</p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Hypertension" frame="border" id="lexi-content-hypertension" rules="all">
<caption style="text-align:center;">
<b>Infliximab: Adverse Reaction: Hypertension</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Infliximab)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Infliximab)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">7%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Rheumatoid arthritis</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1,129</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">350</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Cellulitis, diaphoresis, pruritus (7%)<span class="lexi-table-link-container"> (<a aria-label="Pruritus table link" class="lexi-table-link" data-table-id="lexi-content-pruritus" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-pruritus')">table 4</a>)</span><span class="table-link" style="display:none;">Pruritus</span>, skin rash (10%)<span class="lexi-table-link-container"> (<a aria-label="Skin Rash table link" class="lexi-table-link" data-table-id="lexi-content-skin-rash" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-skin-rash')">table 5</a>)</span><span class="table-link" style="display:none;">Skin Rash</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Pruritus" frame="border" id="lexi-content-pruritus" rules="all">
<caption style="text-align:center;">
<b>Infliximab: Adverse Reaction: Pruritus</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Infliximab)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Infliximab)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">7%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Rheumatoid arthritis</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1,129</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">350</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Skin Rash" frame="border" id="lexi-content-skin-rash" rules="all">
<caption style="text-align:center;">
<b>Infliximab: Adverse Reaction: Skin Rash</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Infliximab)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Infliximab)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">10%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Rheumatoid arthritis</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1,129</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">350</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Dehydration</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Constipation, dyspepsia (10%), intestinal obstruction</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Urinary tract infection (8%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Hemolytic anemia, leukopenia (≤9%;), lymphadenopathy, malignant lymphoma, neutropenia (7%), pancytopenia, thrombocytopenia</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hepatitis</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Hypersensitivity reaction (≤6%), serum sickness (≤1%), type IV hypersensitivity reaction (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Immunologic: Sarcoidosis</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Bacterial infection (6%), candidiasis (5%), sepsis, viral infection (8%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Dizziness, fatigue (9%), pain (8%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia (8%)<span class="lexi-table-link-container"> (<a aria-label="Arthralgia table link" class="lexi-table-link" data-table-id="lexi-content-arthralgia" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-arthralgia')">table 6</a>)</span><span class="table-link" style="display:none;">Arthralgia</span>, bone fracture (7%)</p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Arthralgia" frame="border" id="lexi-content-arthralgia" rules="all">
<caption style="text-align:center;">
<b>Infliximab: Adverse Reaction: Arthralgia</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Infliximab)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Infliximab)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">8%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">7%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Rheumatoid arthritis</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1,129</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">350</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Bronchitis (10%), lower respiratory tract infection, pleurisy, pneumonia (≤2%), pulmonary edema</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (7%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%:</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylaxis</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Coccidioidomycosis, cytomegalovirus disease, herpes zoster infection, histoplasmosis, nocardiosis, opportunistic infection</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Seizure</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Infection due to an organism in genus <i>Pneumocystosis, </i>tuberculosis (including reactivated tuberculosis)</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined: Dermatologic: Dermal ulcer</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Acute myocardial infarction, cardiac arrhythmia, chest discomfort (Lichtenstein 2015), heart failure (Chung 2003), ischemic heart disease, pericardial effusion, vasculitis (systemic and cutaneous), worsening of heart failure (Chung 2003)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Acneiform eruption (Senila 2017), acute generalized exanthematous pustulosis (including acute localized exanthematous pustulosis) (Meiss 2007, Senila 2017), bullous dermatitis (linear IgA) (Bryant 2016), eczematous rash (Moustou 2009), erythema multiforme, lichenoid eruption (Moustou 2009), maculopapular rash (Gamarra 2006), malignant melanoma, Merkel cell carcinoma, psoriasiform eruption (Hawryluk 2012), psoriasis (including exacerbation, new onset, palmoplantar, or pustular), pustular rash (Moustou 2009), Stevens-Johnson syndrome, toxic epidermal necrolysis (Meiss 2007)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Cholestasis, malignant neoplasm of colon or rectum</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Malignant neoplasm of breast, malignant neoplasm of cervix</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Agranulocytosis, hepatosplenic T-cell lymphomas (mainly adolescent or young adult males), Hodgkin lymphoma, immune thrombocytopenia, leukemia, malignant neoplasm, non-Hodgkin lymphoma, thrombotic thrombocytopenic purpura</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Acute hepatic failure (Björnsson 2022), autoimmune hepatitis (Ghabril 2013), cholestatic hepatitis (including vanishing bile duct syndrome) (Björnsson 2022) hepatotoxicity (idiosyncratic) (Björnsson 2022), increased serum transaminases (Shah 2020), jaundice</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylactic shock</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Aspergillosis, atypical mycobacterial infection, blastomycosis, fungal infection, listeriosis, parasitic infection, reactivation of HBV (Loomba 2017)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Cerebrovascular accident, demyelinating disease (peripheral; including chronic inflammatory demyelinating polyneuropathy, Guillain-Barre syndrome, multifocal motor neuropathy) (Kemanetzoglou 2017), demyelinating disease of the central nervous system (including multiple sclerosis) (Kemanetzoglou 2017), neuropathy, transverse myelitis (Kunchok 2020)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Lupus-like syndrome (Choi 2021)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Optic neuritis (Dermawan 2020), temporary vision loss</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Bacterial pneumonia (legionnaires’ disease), bronchospasm, dyspnea (Lichtenstein 2015), interstitial lung disease (including interstitial pneumonitis, pulmonary fibrosis), laryngeal edema, pharyngeal edema</p></div>
<div class="block coi drugH1Div" id="F182743"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Previous severe hypersensitivity (eg, anaphylaxis, hypotension, serum sickness) to infliximab, murine proteins, or any component of the formulation; doses &gt;5 mg/kg in patients with moderate or severe heart failure (NYHA class III/IV).</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in US labeling): Severe infections (eg, sepsis, abscesses, tuberculosis, and opportunistic infections); use in patients with moderate or severe heart failure (NYHA class III/IV).</p></div>
<div class="block war drugH1Div" id="F182727"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Antibody formation: Formation of neutralizing anti-drug antibodies may occur with biologic tumor necrosis factor (TNF) inhibitors and may be associated with loss of efficacy (AAD-NPF [Menter 2019]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiovascular/cerebrovascular reactions during and following infusion: Cerebrovascular accidents, MI (some fatal), hypotension, hypertension, and arrhythmias have been reported within 24 hours of infusion. Transient vision loss has also been reported during or within 2 hours of infusion. Discontinue therapy if serious reaction occurs.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hematologic disorders: Hematologic toxicities (eg, leukopenia, neutropenia, thrombocytopenia, pancytopenia) have been reported (may be fatal).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Active infection: Do not initiate infliximab therapy in patients with an active infection, including clinically important localized infection.</p>
<p style="text-indent:-2em;margin-left:4em;">• HIV: Use with caution in HIV-positive patients; TNF-α inhibitors may be appropriate in patients receiving highly active antiretroviral therapy, provided they have normal CD4 counts, no viral load, and no recent opportunistic infections (AAD-NPF [Menter 2019]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Seizure disorders: Use with caution in patients with a history of seizures; discontinue if significant CNS adverse reactions develop.</p>
<p style="text-indent:-2em;margin-left:4em;">• Solid organ transplant: Consider holding infliximab prior to living donor solid organ transplant (eg, hold IV infliximab for at least 4 weeks; hold SUBQ infliximab for 1 week) (Szczepanik 2022).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Patients with rheumatic musculoskeletal disease undergoing hip or knee replacement surgery: Hold biologic disease-modifying antirheumatic drugs prior to surgery and plan surgery after the next dose is due. Surgery can occur after holding medication for 1 full dosing cycle (eg, for medications administered every 4 weeks, schedule surgery 5 weeks from last administered dose); therapy can be restarted once surgical wound shows evidence of healing (eg, no swelling, erythema, or drainage), sutures/staples are removed, and no ongoing nonsurgical site infections (typically ~14 days to reduce infection risk). Decisions to withhold therapy should be based on shared decision making; ensure the patient and their provider weigh risks of interrupting therapy and disease control versus risks of continuing therapy and surgical complications (ACR/AAHKS [Goodman 2022]).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson 2002; Lucente 2000; Shelley 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade 1986; CDC 1984). See manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Immunizations: Patients should be brought up to date with all immunizations before initiating therapy. Live vaccines should not be given concurrently; there are no data available concerning secondary transmission of live vaccines in patients receiving therapy. A fatal outcome has been reported in an infant who received a live vaccine (BCG) after in utero exposure to infliximab. It is recommended to wait ≥6 months following birth before administering any live vaccine to infants exposed to infliximab in utero (Remsima [Canadian product] recommends waiting until 12 months of age).</p></div>
<div class="block prod-avail drugH1Div" id="F50858894"><span class="drugH1">Product Availability</span>
<p style="text-indent:-2em;margin-left:2em;">Ixifi (infliximab-qbtx): FDA approved December 2017; anticipated availability is currently undetermined.</p>
<p style="text-indent:-2em;margin-left:2em;">Zymfentra: FDA approved October 2023; anticipated availability currently unknown. Information pertaining to this product within the monograph is pending revision. Zymfentra is indicated for subcutaneous administration for the maintenance treatment of moderately to severely active ulcerative colitis or Crohn disease following initial therapy with intravenous infliximab. Consult the prescribing information for additional information.</p></div>
<div class="block dosfc drugH1Div" id="F27749143"><span class="drugH1">Dosage Forms Considerations</span>
<p style="text-indent:0em;display:inline">Remicade contains sucrose 500 mg per vial.</p></div>
<div class="block foc drugH1Div" id="F182738"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Avsola: infliximab-axxq 100 mg (1 ea) [contains polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Inflectra: infliximab-dyyb 100 mg (1 ea) [contains polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Remicade: 100 mg (1 ea) [contains polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Renflexis: infliximab-abda 100 mg (1 ea) [contains polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 100 mg (1 ea)</p></div>
<div class="block geq drugH1Div" id="F182723"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F4370699"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (Avsola Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg (per each): $600.00</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (Inflectra Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg (per each): $1,135.54</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (inFLIXimab Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg (per each): $570.00</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (Remicade Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg (per each): $1,401.38</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (Renflexis Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg (per each): $904.07</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52867204"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Auto-injector Kit, Subcutaneous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Remsima SC: 120 mg/mL (1 ea) [contains polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Avsola: 100 mg (1 ea) [contains polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Inflectra: 100 mg (1 ea) [contains polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Remicade: 100 mg (1 ea) [contains polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Renflexis: 100 mg (1 ea) [contains polysorbate 80]</p></div>
<div class="block admp drugH1Div" id="F52613051"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Parenteral: The infusion should begin within 3 hours (Avsola, Inflectra, Remicade) or 4 hours (Renflexis) of preparation. Administer by IV infusion through an in-line, sterile, nonpyrogenic, low-protein-binding filter with pore size of ≤1.2 micrometers; do not infuse in the same IV line as other agents. The manufacturer recommends to infuse over at least 2 hours; however, rapid infusion times of 1 hour have been described in patients with ulcerative colitis on a stable maintenance dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30044357']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30044357'])">Ref</a></span>); a rate titration schedule may be used to prevent acute infusion reactions. Temporarily discontinue or decrease infusion rate if infusion-related reactions occur. Antihistamines (H<sub>1</sub>-antagonist ± H<sub>2</sub>-antagonist), acetaminophen, and/or corticosteroids may be used to manage infusion reactions. Infusion may be reinitiated at a lower rate upon resolution of mild to moderate symptoms.</p>
<p style="text-indent:-2em;margin-left:2em;">Guidelines for the treatment and prophylaxis of infusion reactions: There are no pediatric-specific guidelines available. In adults, the following protocol for the treatment of infusion reactions, as well as prophylactic therapy for repeat infusions, has been published (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17129817']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17129817'])">Ref</a></span>).</p>
<p style="text-indent:0em;margin-left:2em;margin-top:2em;">
<i>Treatment of infusion reactions:</i> Adults: Medications for the treatment of hypersensitivity reactions should be available for immediate use. For mild reactions, the rate of infusion should be decreased to 10 mL/hour. Initiate an NS infusion (500 to 1,000 mL/hour) and appropriate symptomatic treatment (eg, acetaminophen, diphenhydramine); monitor vital signs every 10 minutes until normal. After 20 minutes, the infliximab infusion may be increased at 15-minute intervals, as tolerated, to completion (initial increase to 20 mL/hour, then 40 mL/hour, then 80 mL/hour, etc [maximum of 125 mL/hour]). For moderate reactions, the infusion should be stopped or slowed. Initiate an NS infusion (500 to 1,000 mL/hour) and appropriate symptomatic treatment. Monitor vital signs every 5 minutes until normal. After 20 minutes, the infliximab infusion may be reinstituted at 10 mL/hour; then increased at 15-minute intervals, as tolerated, to completion (initial increase 20 mL/hour, then 40 mL/hour, then 80 mL/hour, etc [maximum of 125 mL/hour]). For severe reactions, the infusion should be stopped with administration of appropriate symptomatic treatment (eg, hydrocortisone/methylprednisolone, diphenhydramine, epinephrine) and frequent monitoring of vitals. Retreatment after a severe reaction should only be done if the benefits outweigh the risks and with appropriate prophylaxis. Delayed infusion reactions typically occur 1 to 7 days after an infusion. Treatment should consist of appropriate symptomatic treatment (eg, acetaminophen, antihistamine, methylprednisolone).</p>
<p style="text-indent:0em;margin-left:2em;margin-top:2em;">
<i>Prophylaxis of infusion reactions:</i> Adults: Premedication with acetaminophen and diphenhydramine 90 minutes prior to infusion may be considered in all patients with prior infusion reactions, and in patients with severe reactions, corticosteroid administration is recommended. Steroid dosing may be oral (prednisone 50 mg orally every 12 hours for 3 doses prior to infusion) or intravenous (a single dose of hydrocortisone 100 mg or methylprednisolone 20 to 40 mg administered 20 minutes prior to the infusion). Upon initiation of the infusion, begin with a test dose at 10 mL/hour of infliximab for 15 minutes. Thereafter, the infusion may be increased at 15-minute intervals, as tolerated, to completion (initial increase 20 mL/hour, then 40 mL/hour, then 80 mL/hour, etc). A maximum rate of 125 mL/hour is recommended in patients who experienced prior mild-moderate reactions and 100 mL/hour is recommended in patients who experienced prior severe reactions. In patients with cutaneous flushing, aspirin may be considered (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15570667']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15570667'])">Ref</a></span>). For delayed infusion reactions, premedicate with acetaminophen and diphenhydramine 90 minutes prior to infusion. Upon initiation of the infusion, begin with a test dose at 10 mL/hour for 15 minutes. Thereafter, the infusion may be increased to infuse over 3 hours. Postinfusion therapy with acetaminophen for 3 days and an antihistamine for 7 days is recommended. <b>Note:</b> In a trial of pediatric patients, premedication with acetaminophen (20 mg/kg; maximum single dose: 1,000 mg) and cetirizine (0.3 mg/kg if &lt;5 years, 10 mg if ≥5 years) did not significantly impact incidence of infusion-related reactions; patients should be monitored closely (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30311152','lexi-content-ref-30044357','lexi-content-ref-20535789','lexi-content-ref-34300342','lexi-content-ref-31332475']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30311152','lexi-content-ref-30044357','lexi-content-ref-20535789','lexi-content-ref-34300342','lexi-content-ref-31332475'])">Ref</a></span>).</p></div>
<div class="block adm drugH1Div" id="F182740"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV:</b> The infusion should begin within 3 hours of reconstitution and dilution. Infuse over at least 2 hours, although use of shortened infusion duration (eg, 1 hour) has been utilized in patients previously tolerating at least four 2-hour infusions (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30657070','lexi-content-ref-23515325','lexi-content-ref-Remicade.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30657070','lexi-content-ref-23515325','lexi-content-ref-Remicade.1'])">Ref</a></span>); also refer to institution-specific protocols. Do not infuse with other agents; use in-line low protein binding filter (≤1.2 micron). Temporarily discontinue or decrease infusion rate with infusion-related reactions. Antihistamines (H<sub>1</sub>-antagonist +/- H<sub>2</sub>-antagonist), acetaminophen and/or corticosteroids may be used to manage reactions. Infusion may be reinitiated at a lower rate upon resolution of mild to moderate symptoms. Re-treatment in psoriasis patients should be resumed as a scheduled maintenance regimen without any induction doses; use of an induction regimen should be used cautiously for re-treatment of all other patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30772098']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30772098'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;margin-top:2em;">
<b>Recommendations for treatment and prophylaxis of infusion reactions:</b> (<b>Note:</b> Limited to adult patients and dosages used in Crohn disease; prospective data for other populations [pediatrics, other indications/dosing] are not available).</p>
<p style="text-indent:-2em;margin-left:6em;">A protocol for the treatment of infusion reactions, as well as prophylactic therapy for repeat infusions, has been published (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17129817']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17129817'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Treatment of infusion reactions:</i> Medications for the treatment of hypersensitivity reactions should be available for immediate use. For mild reactions, the rate of infusion should be decreased to 10 mL/hour. Initiate a normal saline infusion (500 to 1,000 mL/hour) and appropriate symptomatic treatment (eg, acetaminophen and diphenhydramine); monitor vital signs every 10 minutes until normal. After 20 minutes, the infusion may be increased at 15-minute intervals, as tolerated, to completion (initial increase to 20 mL/hour, then 40 mL/hour, then 80 mL/hour, etc [maximum of 125 mL/hour]). For moderate reactions, the infusion should be stopped or slowed. Initiate a normal saline infusion (500 to 1,000 mL/hour) and appropriate symptomatic treatment. Monitor vital signs every 5 minutes until normal. After 20 minutes, the infusion may be reinstituted at 10 mL/hour; then increased at 15-minute intervals, as tolerated, to completion (initial increase 20 mL/hour, then 40 mL/hour, then 80 mL/hour, etc [maximum of 125 mL/hour]). For severe reactions, the infusion should be stopped with administration of appropriate symptomatic treatment (eg, hydrocortisone/methylprednisolone, diphenhydramine and epinephrine) and frequent monitoring of vitals (consult institutional policies, if available). Re-treatment after a severe reaction should only be done if the benefits outweigh the risks and with appropriate prophylaxis. Delayed infusion reactions typically occur 1 to 7 days after an infusion. Treatment should consist of appropriate symptomatic treatment (eg, acetaminophen, antihistamine, methylprednisolone).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Prophylaxis of infusion reactions:</i> Premedication with acetaminophen and diphenhydramine 90 minutes prior to infusion may be considered in all patients with prior infusion reactions, and in patients with severe reactions corticosteroid administration is recommended. Steroid dosing may be oral (prednisone 50 mg orally every 12 hours for 3 doses prior to infusion) or intravenous (a single dose of hydrocortisone 100 mg or methylprednisolone 20 to 40 mg administered 20 minutes prior to the infusion). On initiation of the infusion, begin with a test dose at 10 mL/hour for 15 minutes. Thereafter, the infusion may be increased at 15-minute intervals, as tolerated, to completion (initial increase 20 mL/hour, then 40 mL/hour, then 80 mL/hour, etc). A maximum rate of 125 mL/hour is recommended in patients who experienced prior mild to moderate reactions and 100 mL/hour is recommended in patients who experienced prior severe reactions. In patients with cutaneous flushing, aspirin may be considered (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15570667']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15570667'])">Ref</a></span>). For delayed infusion reactions, premedicate with acetaminophen and diphenhydramine 90 minutes prior to infusion. On initiation of the infusion, begin with a test dose at 10 mL/hour for 15 minutes. Thereafter, the infusion may be increased to infuse over 3 hours. Postinfusion therapy with acetaminophen for 3 days and an antihistamine for 7 days is recommended.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>SUBQ: Remsima (Canadian product): </b>Allow syringe to warm to room temperature prior to use (30 minutes); do not use heat sources to warm (eg, hot water, microwave). Inject into outer area of upper arms (caregiver only), abdomen (do not use within 5 cm of belly button), or front of thighs. Rotate injection site with each dose; administer at least 3 cm away from previous injection site. Do not administer into bruised, damaged, scarred, or tender skin. Do not use damaged syringe; do not reuse or shake syringe. Administer first dose under supervision of health care provider. After proper training, patients may self-inject, or the patient's caregiver may administer.</p></div>
<div class="block sts drugH1Div" id="F182751"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:-2em;margin-left:2em;">Avsola, Inflectra, Remicade, Renflexis: Store intact vials at 2°C to 8°C (36°F to 46°F); may be stored at room temperature (maximum of 30°C [86°F]) for up to 6 months (not to exceed the original expiration date); do not return to refrigerated storage; protect from light (Avsola labeling only). The manufacturer recommends that administration of solutions diluted in NS for infusion should begin within 3 hours of reconstitution and dilution.</p>
<p style="text-indent:-2em;margin-left:2em;">Remsima (Canadian product): Store at 2°C to 8°C (36°F to 46°F); may be stored at room temperature (maximum of 25°C [77°F]) for up to 28 days. Store in original container to protect from light; do not freeze.</p></div>
<div class="block meg drugH1Div" id="F7874621"><span class="drugH1">Medication Guide and/or Vaccine Information Statement (VIS)</span>
<p style="text-indent:0em;display:inline">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:</p>
<p style="text-indent:-2em;margin-left:4em;">Avsola: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2019%2F761086s000lbl.pdf%23page%3D48&amp;token=CYTm5Va%2Bnnav0RRbAZlrbMu2%2Figp3JjgxyR9Bu%2F4QvdDzknIMT4JUoFDfG%2FDm0aGeyKYiYhLUV1bAJJkvYFlJ5XYaQOFhbtiPmPq%2BsSISnZAoNcYaVtS8qY8Z859uDnY&amp;TOPIC_ID=13381" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761086s000lbl.pdf#page=48</a></p>
<p style="text-indent:-2em;margin-left:4em;">Inflectra: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2021%2F125544s018lbl.pdf%23page%3D61&amp;token=8FtIWsRqmYIvggo%2Foh%2BccvsL9gWqM8rT35OZGPIItDl2RzfYuUtrKSGX9qipCE%2FroNxlo%2BXm0I1Qqb9sFRrkBQ%2BQ8JeYEI633ej%2FDpD%2FNtsWUR2mGvcreDNJshu%2F%2BSYw&amp;TOPIC_ID=13381" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125544s018lbl.pdf#page=61</a></p>
<p style="text-indent:-2em;margin-left:4em;">Ixifi: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2020%2F761072s006lbl.pdf%23page%3D43&amp;token=zUXSmmdZT7WTZ52qJVvUDRVhaTrcTAvtY%2FYdJMVfVVWDYKJA3gRa7dqrDus1XxxkuJ38t4xJciosMfARmrl%2BjLG3B%2Bf16at7sv1kjUlB1bHrubIdqRdTDFnzw8xTTDef&amp;TOPIC_ID=13381" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761072s006lbl.pdf#page=43</a></p>
<p style="text-indent:-2em;margin-left:4em;">Remicade: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2021%2F103772s5401lbl.pdf%23page%3D50&amp;token=MXTHlzu2f6jTWWasC0z83Oqnl%2FvC7h0u9788sfpHU%2F9DYEXqd9LJBjpAIOvA9LGLG5z4UQwD0n18EnBb9TjOINPuggQwF4%2FIQ1r6Y85lM4kwW2kVWgNOywbR5N4E%2B2sG&amp;TOPIC_ID=13381" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/103772s5401lbl.pdf#page=50</a></p>
<p style="text-indent:-2em;margin-left:4em;">Renflexis: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2019%2F761054s004lbl.pdf%23page%3D52&amp;token=JnXXn9oB5DKV1h0OTu02yGCDEQ4C3kMLcOF1Slcd598h7cbohVJ5aJRqykD%2FoIs9UcPX3fqe5E6j4K9X0%2BlXdb14pTKVwayyonEEHukM6Hw99wHc4tOlGrZEfhC%2BYxnk&amp;TOPIC_ID=13381" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761054s004lbl.pdf#page=52</a></p>
<p style="text-indent:-2em;margin-left:4em;">Zymfentra: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2023%2F761358s000lbl.pdf%23page%3D30&amp;token=3MKFp34pKlgNzbCtLoWCmf89ny8IjZ4AbdrclMoZtvj7ii2SFL8fHyHy1lZwVTbexBHGMCvNQfIFLGrteCHwNwi92KFACGjQggkPIhJz9ieYizUGy%2FTs4pfliZTitfql&amp;TOPIC_ID=13381" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761358s000lbl.pdf#page=30</a></p></div>
<div class="block usep drugH1Div" id="F53567324"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Treatment of patients with moderately to severely active Crohn disease who have had inadequate response to conventional therapy, to reduce signs/symptoms and induce and maintain clinical remission (FDA approved in ages ≥6 years and adults), and to reduce the number of draining enterocutaneous and rectovaginal fistulas (FDA approved in adults); treatment of patients with moderately to severely active ulcerative colitis with inadequate response to conventional therapy, to reduce signs/symptoms and induce and maintain clinical remission (FDA approved in ages ≥6 years and adults), and to induce/maintain mucosal healing and eliminate corticosteroid use (FDA approved in adults); treatment of patients with moderately to severely active rheumatoid arthritis (in combination with methotrexate) (FDA approved in adults); reduction of signs and symptoms of ankylosing spondylitis (FDA approved in adults); treatment of psoriatic arthritis (FDA approved in adults); treatment of chronic severe (extensive and/or disabling) plaque psoriasis in patients who require systemic therapy and when other systemic therapies are less appropriate (FDA approved in adults); has also been used for management of Kawasaki disease refractory to intravenous immunoglobulin (IVIG) and multisystem inflammatory syndrome in children (MIS-C) associated with SARS-CoV-2.</p>
<p style="text-indent:0em;margin-top:2em;">
<b>Note:</b> Avsola (infliximab-axxq), Inflectra (infliximab-dyyb), Ixifi (infliximab-qbtx), and Renflexis (infliximab-abda) are biosimilar agents; approved uses and ages may vary; see product labeling for additional information.</p></div>
<div class="block mst drugH1Div" id="F182793"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues: </span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">InFLIXimab may be confused with idaruCIZUmab, riTUXimab</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Remicade may be confused with Renacidin, Rituxan</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes that have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299517"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F182732"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Abatacept: Anti-TNF Agents may enhance the immunosuppressive effect of Abatacept. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Abrocitinib: May enhance the immunosuppressive effect of Immunosuppressants (Therapeutic Immunosuppressant Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anakinra: Anti-TNF Agents may enhance the adverse/toxic effect of Anakinra. An increased risk of serious infection during concomitant use has been reported. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anifrolumab: Biologic Disease-Modifying Antirheumatic Drugs (DMARDs) may enhance the immunosuppressive effect of Anifrolumab. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antithymocyte Globulin (Equine): Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Antithymocyte Globulin (Equine). Specifically, these effects may be unmasked if the dose of immunosuppressive therapy is reduced. Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Antithymocyte Globulin (Equine). Specifically, infections may occur with greater severity and/or atypical presentations. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">AzaTHIOprine: InFLIXimab may enhance the adverse/toxic effect of AzaTHIOprine. Specifically, the risk for T-cell non-Hodgkin's lymphoma (including hepatosplenic T-cell lymphoma) may be increased. InFLIXimab may increase serum concentrations of the active metabolite(s) of AzaTHIOprine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Baricitinib: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Baricitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG Products: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of BCG Products. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of BCG Products. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Belimumab: May enhance the immunosuppressive effect of Biologic Disease-Modifying Antirheumatic Drugs (DMARDs). Management: Consider alternatives to the use of belimumab with other biologic therapies. Monitor closely for increased toxicities related to additive immunosuppression (ie, infection, malignancy) if combined.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Biologic Anti-Psoriasis Agents: InFLIXimab may enhance the immunosuppressive effect of Biologic Anti-Psoriasis Agents. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Biologic Disease-Modifying Antirheumatic Drugs (DMARDs): May enhance the immunosuppressive effect of other Biologic Disease-Modifying Antirheumatic Drugs (DMARDs).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brincidofovir: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Brincidofovir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brivudine: May enhance the adverse/toxic effect of Immunosuppressants (Therapeutic Immunosuppressant Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Canakinumab: Anti-TNF Agents may enhance the adverse/toxic effect of Canakinumab. Specifically, the risk for serious infections and/or neutropenia may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Certolizumab Pegol: Anti-TNF Agents may enhance the immunosuppressive effect of Certolizumab Pegol. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chikungunya Vaccine (Live): Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Chikungunya Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Chikungunya Vaccine (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Cladribine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Coccidioides immitis Skin Test: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the diagnostic effect of Coccidioides immitis Skin Test.  Management: Consider discontinuing therapeutic immunosuppressants several weeks prior to coccidioides immitis skin antigen testing to increase the likelihood of accurate diagnostic results.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Adenovirus Vector): Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of COVID-19 Vaccine (Adenovirus Vector).  Management: Administer a 2nd dose using an mRNA COVID-19 vaccine (at least 4 weeks after the primary vaccine dose) and a bivalent booster dose (at least 2 months after the additional mRNA dose or any other boosters).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Inactivated Virus): Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of COVID-19 Vaccine (Inactivated Virus). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (mRNA): Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of COVID-19 Vaccine (mRNA).  Management: Give a 3-dose primary series for all patients aged 6 months and older taking immunosuppressive medications or therapies. Booster doses are recommended for certain age groups. See CDC guidance for details.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Subunit): Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of COVID-19 Vaccine (Subunit). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Virus-like Particles): Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of COVID-19 Vaccine (Virus-like Particles). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dengue Tetravalent Vaccine (Live): Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Dengue Tetravalent Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Dengue Tetravalent Vaccine (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Denosumab: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Denosumab.  Management: Consider the risk of serious infections versus the potential benefits of coadministration of denosumab and immunosuppressants. If combined, monitor for signs/symptoms of serious infections.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deucravacitinib: May enhance the immunosuppressive effect of Immunosuppressants (Therapeutic Immunosuppressant Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Efgartigimod Alfa: May diminish the therapeutic effect of Fc Receptor-Binding Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etrasimod: May enhance the immunosuppressive effect of Immunosuppressants (Therapeutic Immunosuppressant Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Filgotinib: May enhance the immunosuppressive effect of Immunosuppressants (Therapeutic Immunosuppressant Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Inebilizumab: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Inebilizumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Influenza Virus Vaccines: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Influenza Virus Vaccines.  Management: Administer influenza vaccines at least 2 weeks prior to initiating immunosuppressants if possible. If vaccination occurs less than 2 weeks prior to or during therapy, revaccinate 2 to 3 months after therapy discontinued if immune competence restored.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Leflunomide: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Leflunomide.  Management: Increase the frequency of chronic monitoring of platelet, white blood cell count, and hemoglobin or hematocrit to monthly, instead of every 6 to 8 weeks, if leflunomide is coadministered with immunosuppressive agents.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mumps- Rubella- or Varicella-Containing Live Vaccines: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Mumps- Rubella- or Varicella-Containing Live Vaccines. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Mumps- Rubella- or Varicella-Containing Live Vaccines. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nadofaragene Firadenovec: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Nadofaragene Firadenovec. Specifically, the risk of disseminated adenovirus infection may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Natalizumab: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Natalizumab. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ocrelizumab: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Ocrelizumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ofatumumab: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Ofatumumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pidotimod: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Pidotimod. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pimecrolimus: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Pimecrolimus. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pneumococcal Vaccines: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Pneumococcal Vaccines. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Poliovirus Vaccine (Live/Trivalent/Oral): Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Poliovirus Vaccine (Live/Trivalent/Oral). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Poliovirus Vaccine (Live/Trivalent/Oral). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Polymethylmethacrylate: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the potential for allergic or hypersensitivity reactions to Polymethylmethacrylate.  Management: Use caution when considering use of bovine collagen-containing implants such as the polymethylmethacrylate-based Bellafill brand implant in patients who are receiving immunosuppressants. Consider use of additional skin tests prior to administration.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rabies Vaccine: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Rabies Vaccine.  Management: Complete rabies vaccination at least 2 weeks before initiation of immunosuppressant therapy if possible. If combined, check for rabies antibody titers, and if vaccination is for post exposure prophylaxis, administer a 5th dose of the vaccine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rilonacept: Anti-TNF Agents may enhance the adverse/toxic effect of Rilonacept. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ritlecitinib: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Ritlecitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rozanolixizumab: May diminish the therapeutic effect of Fc Receptor-Binding Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ruxolitinib (Topical): Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Ruxolitinib (Topical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sipuleucel-T: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Sipuleucel-T.  Management: Consider reducing the dose or discontinuing the use of immunosuppressants prior to initiating sipuleucel-T therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sphingosine 1-Phosphate (S1P) Receptor Modulator: May enhance the immunosuppressive effect of Immunosuppressants (Therapeutic Immunosuppressant Agents).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Topical): Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Tacrolimus (Topical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Talimogene Laherparepvec: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Talimogene Laherparepvec. Specifically, the risk of infection from the live, attenuated herpes simplex virus contained in talimogene laherparepvec may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tertomotide: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Tertomotide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thiopurine Analogs: Anti-TNF Agents may enhance the adverse/toxic effect of Thiopurine Analogs. Specifically, the risk for T-cell non-Hodgkin's lymphoma (including hepatosplenic T-cell lymphoma) may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tofacitinib: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Tofacitinib.  Management: Coadministration of tofacitinib with potent immunosuppressants is not recommended. Use with non-biologic disease-modifying antirheumatic drugs (DMARDs) was permitted in psoriatic arthritis clinical trials.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Typhoid Vaccine: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Typhoid Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Typhoid Vaccine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ublituximab: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Ublituximab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Upadacitinib: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Upadacitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vaccines (Inactivated/Non-Replicating): Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Vaccines (Inactivated/Non-Replicating).  Management: Give inactivated vaccines at least 2 weeks prior to initiation of immunosuppressants when possible. Patients vaccinated less than 14 days before initiating or during therapy should be revaccinated at least 2 to 3 months after therapy is complete.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vaccines (Live): Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Vaccines (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Vaccines (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vedolizumab: Anti-TNF Agents may enhance the adverse/toxic effect of Vedolizumab. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Yellow Fever Vaccine: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Yellow Fever Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Yellow Fever Vaccine. <i> Risk X: Avoid combination</i></p></div>
<div class="block rep_considerations drugH1Div" id="F53669418"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Infliximab may be used in patients with rheumatic and musculoskeletal diseases who are planning to become pregnant. Conception should be planned during a period of quiescent/low disease activity (ACR [Sammaritano 2020]).</p>
<p style="text-indent:0em;margin-top:2em;">Patients with psoriasis planning to become pregnant may continue treatment with infliximab. Patients with well-controlled psoriasis who wish to avoid fetal exposure can consider discontinuing infliximab 50 days prior to attempting to become pregnant (Rademaker 2018).</p>
<p style="text-indent:0em;margin-top:2em;">Biologics, such as infliximab, may be continued in patients with inflammatory bowel disease planning to become pregnant (Mahadevan 2019). Treatment algorithms are available for use of biologics in patients with Crohn disease who are planning to become pregnant (Weizman 2019). Serum levels should be optimized prior to conception (Mahadevan 2019).</p>
<p style="text-indent:0em;margin-top:2em;">Infliximab is recommended for use in patients with rheumatic and musculoskeletal diseases who are planning to father a child (ACR [Sammaritano 2020]).</p>
<p style="text-indent:0em;margin-top:2em;">The American Academy of Dermatology considers tumor necrosis factor alpha (TNFα)-blocking agents for the treatment of psoriasis to be compatible for use in patients planning to father a child (AAD-NPF [Menter 2019]).</p></div>
<div class="block pri drugH1Div" id="F182745"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Infliximab crosses the placenta.</p>
<p style="text-indent:0em;margin-top:2em;">Infliximab is a chimeric monoclonal antibody (IgG<sub>1</sub>). Human IgG crosses the placenta. Fetal exposure is dependent upon the IgG subclass, maternal serum concentrations, placental integrity, newborn birth weight, and GA, generally increasing as pregnancy progresses. The lowest exposure would be expected during the period of organogenesis and the highest during the third trimester (Clements 2020; Palmeira 2012; Pentsuk 2009).</p>
<p style="text-indent:0em;margin-top:2em;">In some cases, cord blood and newborn concentrations of infliximab may be greater than maternal serum at delivery (Ghalandari 2022; Julsgaard 2016; Mahadevan 2013). This was also observed with an infliximab biosimilar (infliximab-dyyb) (Kawamoto 2022). There is an inverse correlation between the duration since last maternal dose and cord blood concentrations at delivery (Ghalandari 2022; Julsgaard 2016; Mahadevan 2013). The mean time to infliximab clearance was 7.3 months (range: 6.2 to 8.3 months) in a study in 44 infants exposed in utero (last maternal dose at 30 weeks' gestation [mean; range 8 to 37 weeks]). Infliximab serum concentrations remained detectable in one infant until 12 months of age (Julsgaard 2016). Discontinuing infliximab prior to 20 weeks' gestation resulted in undetectable or low cord blood concentrations in one study of 14 patients (Ghalandari 2022).</p>
<p style="text-indent:0em;margin-top:2em;">Outcome data following maternal use of infliximab are available (Geldhof 2020; MacIsaac 2022; Wang 2022). Based on available data, product labeling notes an increased risk of major birth defects has not been observed following infliximab exposure during pregnancy. Data related to this class of medications are emerging, but based on available data, tumor necrosis factor alpha (TNFα)-blocking agents are considered to have low to moderate risk when used in pregnancy (ACOG 2019).</p>
<p style="text-indent:0em;margin-top:2em;">A paper describes agranulocytosis requiring treatment with granulocyte colony stimulating factor in four infants (3 of which were triplets) exposed to infliximab in utero. In the singleton pregnancy, infliximab was present in the newborn serum 13 weeks after the last maternal pregnancy dose, but concentrations were not measurable in the mother. Infliximab serum concentrations were not evaluated in the triplets (Guiddir 2014).</p>
<p style="text-indent:0em;margin-top:2em;">Adverse outcomes, including fatalities, have been reported in infants who received the live BCG vaccine after in utero exposure to infliximab (Goulden 2022). The risk of immunosuppression may be increased following third trimester maternal use of TNFα-blocking agents; the fetus, neonate/infant should be considered immunosuppressed following in utero exposure (AAD-NPF [Menter 2019]). Vaccination with live vaccines (eg, rotavirus vaccine) should be avoided for the first 6 months of life if exposure to a biologic agent occurs during the third trimester of pregnancy (eg, &gt;27 weeks' gestation) (Mahadevan 2019).</p>
<p style="text-indent:0em;margin-top:2em;">Due to pregnancy-induced physiologic changes, some pharmacokinetic properties of infliximab may be altered. Clearance may be decreased as pregnancy progresses leading to an increase in maternal plasma concentrations; therapeutic drug monitoring may be required in some patients (Wiersma 2022).</p>
<p style="text-indent:0em;margin-top:2em;">Recommendations for use of infliximab during pregnancy vary by indication and guideline (Romanowska-Próchnicka 2021). Use of immune-modulating therapies in pregnancy should be individualized to optimize maternal disease and pregnancy outcomes (ACOG 2019).</p>
<p style="text-indent:0em;margin-top:2em;">The American Academy of Dermatology (AAD) considers TNFα-blocking agents for the treatment of psoriasis to be compatible with pregnancy (AAD-NPF [Menter 2019]).</p>
<p style="text-indent:0em;margin-top:2em;">Inflammatory bowel disease is associated with adverse pregnancy outcomes, including an increased risk of miscarriage, premature delivery, delivery of a low-birth-weight infant, and poor maternal weight gain. Management of maternal disease should be optimized prior to pregnancy. Treatment decreases disease flares, disease activity, and the incidence of adverse pregnancy outcomes (Mahadevan 2019). When treatment for inflammatory bowel disease is needed in pregnant patients, the American Gastroenterological Association notes appropriate biologic therapy can be continued without interruption. Weight based dosing can be done using prepregnancy body weight and adjusted as needed based on disease activity and serum concentrations. Serum levels should be evaluated prior to conception and optimized to avoid subtherapeutic concentrations or high levels, which may increase placental transfer. Dosing can be adjusted so delivery occurs at the lowest serum concentration. For infliximab, the final injection can be given 6 to 10 weeks prior to the estimated date of delivery, then restarted 48 hours postpartum (Mahadevan 2019).</p>
<p style="text-indent:0em;margin-top:2em;">According to the American College of Rheumatology, infliximab may be continued during the first and second trimesters of pregnancy in patients with rheumatic and musculoskeletal diseases. Use should be discontinued during the third trimester in patients with well-controlled disease. Newborn exposure should be considered if treatment cannot be discontinued due to active disease (ACR [Sammaritano 2020]).</p>
<p style="text-indent:0em;margin-top:2em;">Infliximab is also used off label for the treatment of COVID-19. The risk of severe morbidity and mortality from COVID-19 infection is increased in symptomatic pregnant patients compared to nonpregnant patients. Pregnant and recently pregnant patients with moderate or severe infection are at increased risk of complications such as hypertensive disorders of pregnancy, postpartum hemorrhage, or other infections compared to pregnant patients without COVID-19. Symptomatic pregnant patients may require ICU admission, mechanical ventilation, or ventilatory support (ECMO). Other adverse pregnancy outcomes include preterm birth and stillbirth. The risk of coagulopathy, cesarean delivery, and maternal death may be increased; neonates have an increased risk for NICU admission. Maternal age and comorbidities such as diabetes, hypertension, lung disease, and obesity may also increase the risk of severe illness in pregnant and recently pregnant patients (ACOG 2023; NIH 2023).</p>
<p style="text-indent:0em;margin-top:2em;">In general, the treatment of COVID-19 infection during pregnancy is the same as in nonpregnant patients; however, because data for most therapeutic agents in pregnant patients are limited, treatment options should be evaluated as part of a shared decision-making process. Pregnancy is a risk factor for severe COVID-19. The use of infliximab in hospitalized pregnant patients is recommended if indicated when other agents are not available or feasible to use; also consider GA of the fetus (NIH 2023). Information related to the treatment of COVID-19 during pregnancy continues to emerge; refer to current guidelines for the treatment of pregnant patients.</p>
<p style="text-indent:0em;margin-top:2em;">Data collection to monitor maternal and infant outcomes following exposure to COVID-19 during pregnancy is ongoing. Health care providers are encouraged to enroll patients exposed to COVID-19 during pregnancy in the Organization of Teratology Information Specialists pregnancy registry (1-877-311-8972; https://mothertobaby.org/join-study/).</p></div>
<div class="block mopp drugH1Div" id="F53567323"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">CBC with differential (baseline and at least every 6 to 12 months); LFTs; hepatitis B virus (HBV) screening prior to initiating (all patients), HBV reactivation (in HBV carriers during and for several months following therapy); latent tuberculosis screening prior to initiating and during therapy; signs/symptoms/worsening of heart failure; signs and symptoms of hypersensitivity reaction; symptoms of lupus-like syndrome; signs and symptoms of malignancy (eg, splenomegaly, hepatomegaly, abdominal pain, persistent fever, night sweats, weight loss); signs/symptoms of infection (prior to, during, and following therapy). During infusion, if reaction is noted, monitor vital signs every 2 to 10 minutes, depending on reaction severity, until normal.</p>
<p style="text-indent:-2em;margin-left:2em;">Patients with psoriasis and a history of phototherapy should be monitored for nonmelanoma skin cancer.</p>
<p style="text-indent:-2em;margin-left:2em;">Monitor serum trough concentrations in patients with inflammatory bowel disease (ECCO-ESPGHAN [Turner 2018a]; ECCO-ESPGHAN [Turner 2018b]; ECCO-ESPGHAN [van Rheenen 2020]; NASPGHAN [Rufo 2012]; Winter 2020).</p></div>
<div class="block rerp drugH1Div" id="F57495732"><span class="drugH1">Reference Range</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>Crohn disease</i> (ECCO-ESPGHAN [van Rheenen 2020]):</p>
<p style="text-indent:-2em;margin-left:4em;">Timing: Obtain trough concentration prior to the fourth infusion (14 weeks after the first dose); for patients at risk of accelerated clearance (eg, weight &lt;30 kg, extensive disease, low serum albumin), may obtain prior to the second or third infusion. Also monitor if patient experiences loss of response.</p>
<p style="text-indent:-2em;margin-left:4em;">Target:</p>
<p style="text-indent:-2em;margin-left:6em;">Induction: Prior to second dose: ≥25 mcg/mL; Prior to third dose: ≥15 mcg/mL.</p>
<p style="text-indent:-2em;margin-left:6em;">Maintenance treatment: ≥5 mcg/mL (ECCO-ESPGHAN [van Rheenen 2020]); a lower target of ≥3 mcg/mL has also been suggested (Winter 2020).</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Ulcerative colitis:</i></p>
<p style="text-indent:-2em;margin-left:4em;">Timing: Obtain trough concentration prior to a maintenance infusion (ie, week 14 or after) and if secondary loss of response occurs (ECCO-ESPGHAN [Turner 2018a]; ECCO-ESPGHAN [Turner 2018b]).</p>
<p style="text-indent:-2em;margin-left:4em;">Maintenance treatment: ≥4 to 5 mcg/mL (ECCO-ESPGHAN [Turner 2018a]); acute severe steroid-refractory disease: 5 to 10 mcg/mL (ECCO-ESPGHAN [Turner 2018b]).</p></div>
<div class="block pha drugH1Div" id="F182726"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Infliximab is a chimeric monoclonal antibody that binds to human tumor necrosis factor alpha (TNFα), thereby interfering with endogenous TNFα activity. Elevated TNFα levels have been found in involved tissues/fluids of patients with rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, plaque psoriasis, Crohn disease and ulcerative colitis. Biological activities of TNFα include the induction of proinflammatory cytokines (interleukins), enhancement of leukocyte migration, activation of neutrophils and eosinophils, and the induction of acute phase reactants and tissue degrading enzymes. Animal models have shown TNFα expression causes polyarthritis, and infliximab can prevent disease as well as allow diseased joints to heal.</p></div>
<div class="block phk drugH1Div" id="F182742"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> Pharmacokinetic data in pediatric patients (6 to 17 years) reported to be similar to adult values.</p>
<p style="text-indent:-2em;margin-left:2em;">Onset of action: Crohn disease: 1 to 2 weeks; Rheumatoid arthritis: 3 to 7 days; Psoriasis: 8 to 10 weeks (AAD-NPF [Menter 2019]).</p>
<p style="text-indent:-2em;margin-left:2em;">Duration of action: Crohn disease: 8 to 48 weeks; Rheumatoid arthritis: 6 to 12 weeks.</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: Within the vascular compartment; V<sub>d</sub>: 3 to 6 L (Klotz 2007); Remsima (Canadian product): Terminal phase: 7.3 to 8.8 L.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: 7 to 12 days (Klotz 2007); Remsima (Canadian product): Terminal: 11.3 to 13.7 days.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F182747"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Ixifi | Remicade | Remsima</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Ixifi | Remicade | Remsima</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Flixabi | Inflectra | Remicade | Remsima | Zessly</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Inflectra | Remicade | Remsima | Renflexis</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Remicade</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Flixabi | Inflectra | Remicade | Remsima | Zessly</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Inflectra | Remicade | Remsima | Zessly</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Avsola | Bio manguinhos infliximabe | Remicade | Remsima | Renflexis | Xilfya</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Inflectra | Remicade | Remicade lyophilisat | Remsima | Veblocema</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Remicade | Remsima</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Remicade</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Remicade | Remsima</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Flixabi | Inflectra | Remicade | Remsima | Zessly</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Flixabi | Inflectra | Remicade | Remsima | Remsima sc | Zessly</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Remicade</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Remicade</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Flixabi | Inflectra | Remicade | Remsima | Zessly</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Remicade</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Flixabi | Inflectra | Remsima | Zessly</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Flixabi | Inflectra | Remicade | Remsima | Zessly</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Flixabi | Inflectra | Remicade | Remsima | Zessly</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Flixabi | Inflectra | Remicade | Remsima | Zessly</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Inflectra | Remicade | Remsima | Zessly</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Remicade | Remsima</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Inflectra | Remicade | Remsima | Zessly</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Inflectra | Remicade | Remsima | Zessly</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Flixabi | Inflectra | Remicade | Remsima</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Remicade</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Infimab</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Flixabi | Inflectra | Remicade | Remsima | Zessly</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Remsima</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Remicade</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Remicade</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Remaloce | Remicade | Remsima | Remsima sc | Renflexis</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Remicade | Remsima</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Ixifi | Remicade | Remsima</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Flixabi | Inflectra | Remicade | Remsima | Zessly</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Remsima</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Remsima | Zessly</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Remicade | Remsima</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Ixifi | Remicade | Remsima</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Remicade | Remsima</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Flixabi | Inflectra | Remicade | Remsima | Zessly</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Flixabi | Inflectra | Remicade | Remsima | Zessly</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Remicade</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Flixceli | Remicade</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Remicade</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Remicade | Remsima</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Flixabi | Inflectra | Remicade | Remsima | Zessly</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Remicade</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Flixabi | Inflectra | Remicade | Remsima | Zessly</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Remsima</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Ixifi | Remicade | Remsima | Renflexis</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Inflectra | Remicade | Remsima | Zessly</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Flammegis | Remicade | Remicaid</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Ixifi | Remicade | Remsima</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Flixabi | Inflectra | Remicade | Remsima | Zessly</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Remicade | Remsima</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Flixabi | Inflectra | Remicade | Remsima | Zessly</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Inflectra | Remicade | Remsima | Zessly</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Remicade | Remsima</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Remicade | Remsima</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Ixifi | Remicade | Remsima</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Remicade | Remsima</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Flammegis | Remicade | Remicaide</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Remicade</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Remicade</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Remiflix | Remsima | Revellex</span>;</li>
<li>
<span class="countryCode">(ZM)</span> <span class="country">Zambia</span><span class="countrySeparator">: </span><span class="drugName">Remicade</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-16371767">
<a name="16371767"></a>Abedin M, Scheurich D, Reimold SC, Reimold AM. Acute coronary syndrome after infliximab infusion. <i>Cardiol Rev</i>. 2006;14(1):50-52. doi:10.1097/01.crd.0000178320.51474.ac<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/16371767/pubmed" id="16371767" target="_blank">16371767</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33318791">
<a name="33318791"></a>Aby ES, Lake JR, Vaughn BP. The impact of biologics for the management of inflammatory bowel disease on liver enzymes. <i>Clin Liver Dis (Hoboken)</i>. 2020;16(5):212-217. doi:10.1002/cld.1005<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/33318791/pubmed" id="33318791" target="_blank">33318791</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26472414">
<a name="26472414"></a>Ai JW, Zhang S, Ruan QL, et al. The risk of tuberculosis in patients with rheumatoid arthritis treated with tumor necrosis factor-α antagonist: a metaanalysis of both randomized controlled trials and registry/cohort studies. <i>J Rheumatol</i>. 2015;42(12):2229-2237. doi:10.3899/jrheum.150057<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/26472414/pubmed" id="26472414" target="_blank">26472414</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3960626">
<a name="3960626"></a>Alade SL, Brown RE, Paquet A. Polysorbate 80 and E-Ferol toxicity. <i>Pediatrics.</i> 1986;77(4):593-597.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/3960626/pubmed" id="3960626" target="_blank">3960626</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32895360">
<a name="32895360"></a>Almeida DE, Costa E, Neves JS, Cerqueira M, Ribeiro AR. Cutaneous vasculitis and granulomatous hepatitis as paradoxical adverse events of Infliximab. <i>Acta Reumatol Port</i>. 2020;45(2):156-157.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/32895360/pubmed" id="32895360" target="_blank">32895360</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34858738">
<a name="34858738"></a>Almuntashri F, Binyaseen K, Alkhotani A. Chronic inflammatory demyelinating polyneuropathy in patients with Crohn's disease on infliximab therapy. <i>Cureus</i>. 2021;13(10):e19041. doi:10.7759/cureus.19041<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/34858738/pubmed" id="34858738" target="_blank">34858738</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30913201">
<a name="30913201"></a>American College of Obstetricians and Gynecologists (ACOG). ACOG committee opinion no. 776: immune modulating therapies in pregnancy and lactation. <i>Obstet Gynecol</i>. 2019;133(4):e287-e295.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/30913201/pubmed" id="30913201" target="_blank">30913201</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ACOG.1">
<a name="ACOG.1"></a>American College of Obstetricians and Gynecologists (ACOG). COVID-19 FAQs for obstetricians-gynecologists, obstetrics. https://www.acog.org/clinical-information/physician-faqs/covid-19-faqs-for-ob-gyns-obstetrics. Accessed December 4, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10881762">
<a name="10881762"></a>American Thoracic Society. Targeted tuberculin testing and treatment of latent tuberculosis infection. <i>MMWR Recomm Rep</i>. 2000;49(RR-6):1-51<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/10881762/pubmed" id="10881762" target="_blank">10881762</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33956488">
<a name="33956488"></a>Anderson PO. Monoclonal antibodies during breastfeeding. <i>Breastfeed Med</i>. 2021;16(8):591-593. doi:10.1089/bfm.2021.0110<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/33956488/pubmed" id="33956488" target="_blank">33956488</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20038753">
<a name="20038753"></a>Angel K, Provan SA, Gulseth HL, Mowinckel P, Kvien TK, Atar D. Tumor necrosis factor-alpha antagonists improve aortic stiffness in patients with inflammatory arthropathies: a controlled study. <i>Hypertension</i>. 2010;55(2):333-338. doi:10.1161/HYPERTENSIONAHA.109.143982<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/20038753/pubmed" id="20038753" target="_blank">20038753</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15818699">
<a name="15818699"></a>Antoni CE, Kavanaugh A, Kirkham B, et al. Sustained Benefits of Infliximab Therapy for Dermatologic and Articular Manifestations of Psoriatic Arthritis: Results from the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT). <i>Arthritis Rheum</i>. 2005;52(4):1227-1236.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/15818699/pubmed" id="15818699" target="_blank">15818699</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24458537">
<a name="24458537"></a>Arts EE, Fransen J, den Broeder AA, Popa CD, van Riel PL. The effect of disease duration and disease activity on the risk of cardiovascular disease in rheumatoid arthritis patients. <i>Ann Rheum Dis</i>. 2015;74(6):998-1003. doi:10.1136/annrheumdis-2013-204531<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/24458537/pubmed" id="24458537" target="_blank">24458537</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18467516">
<a name="18467516"></a>Askling J, Baecklund E, Granath F et al. Anti-tumour necrosis factor therapy in rheumatoid arthritis and risk of malignant lymphomas: relative risks and time trends in the Swedish Biologics Register. <i>Ann Rheum Dis</i>. 2009;68(5):648-653. doi:10.1136/ard.2007.085852<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/18467516/pubmed" id="18467516" target="_blank">18467516</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15829572">
<a name="15829572"></a>Askling J, Fored CM, Brandt L, et al. Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists. <i>Ann Rheum Dis</i>. 2005;64(10):1421-1426. doi:10.1136/ard.2004.033993<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/15829572/pubmed" id="15829572" target="_blank">15829572</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30637218">
<a name="30637218"></a>Averbukh LD, Wu GY. Role of biologics in the development of autoimmune hepatitis: a review. <i>J Clin Transl Hepatol</i>. 2018;6(4):402-409. doi:10.14218/JCTH.2018.00039<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/30637218/pubmed" id="30637218" target="_blank">30637218</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Avsola (infliximab-axxq) [prescribing information]. Thousand Oaks, CA: Amgen Inc; September 2021.</div>
</li>
<li>
<div class="reference">
                  Avsola (infliximab) [product monograph]. Mississauga, Ontario, Canada: Amgen Canada Inc; March 2020.</div>
</li>
<li>
<div class="reference">
                  Avsola (infliximab) [product monograph]. Mississauga, Ontario, Canada: Amgen Canada Inc; May 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29869804">
<a name="29869804"></a>Bae JM, Lee HH, Lee BI. Incidence of psoriasiform diseases secondary to tumour necrosis factor antagonists in patients with inflammatory bowel disease: a nationwide population-based cohort study. <i>Aliment Pharmacol Ther</i>. 2018;48(2):196-205. doi:10.1111/apt.14822<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/29869804/pubmed" id="29869804" target="_blank">29869804</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16840744">
<a name="16840744"></a>Baughman RP, Drent M, Kavuru M, et al; Sarcoidosis Investigators. Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement. <i>Am J Respir Crit Care Med</i>. 2006;174(7):795-802. doi:10.1164/rccm.200603-402OC<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/16840744/pubmed" id="16840744" target="_blank">16840744</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34140301">
<a name="34140301"></a>Baughman RP, Valeyre D, Korsten P, et al. ERS clinical practice guidelines on treatment of sarcoidosis. <i>Eur Respir J.</i> 2021;58(6):2004079. doi:10.1183/13993003.04079-2020<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/34140301/pubmed" id="34140301" target="_blank">34140301</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15570667">
<a name="15570667"></a>Becker M, Rose CD, and McIlvain-Simpson G. Niacin-Like Reaction to Infliximab Infusion in Systemic Juvenile Rheumatoid Arthritis. <i>J Rheumatol</i>. 2004;31(12):2529-2530.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/15570667/pubmed" id="15570667" target="_blank">15570667</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22115374">
<a name="22115374"></a>Ben-Horin S, Yavzori M, Kopylov U, et al. Detection of infliximab in breast milk of nursing mothers with inflammatory bowel disease. <i>J Crohns Colitis</i>. 2011;5(6):555-558.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/22115374/pubmed" id="22115374" target="_blank">22115374</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25131534">
<a name="25131534"></a>Björnsson ES, Gunnarsson BI, Gröndal G, et al. Risk of drug-induced liver injury from tumor necrosis factor antagonists. <i>Clin Gastroenterol Hepatol</i>. 2015;13(3):602-608. doi:10.1016/j.cgh.2014.07.062<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/25131534/pubmed" id="25131534" target="_blank">25131534</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34487751">
<a name="34487751"></a>Björnsson HK, Gudbjornsson B, Björnsson ES. Infliximab-induced liver injury: clinical phenotypes, autoimmunity and the role of corticosteroid treatment. <i>J Hepatol</i>. 2022;76(1):86-92. doi:10.1016/j.jhep.2021.08.024<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/34487751/pubmed" id="34487751" target="_blank">34487751</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33151572">
<a name="33151572"></a>Boggs JME, Ramsay B, Lynch M. Paradoxical psoriasis caused by tumour necrosis factor inhibitor therapy. <i>Clin Exp Dermatol</i>. 2021;46(3):580-582. doi:10.1111/ced.14500<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/33151572/pubmed" id="33151572" target="_blank">33151572</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16705109">
<a name="16705109"></a>Bongartz T, Sutton AJ, Sweeting MJ, et al. Anti-TNF Antibody Therapy In Rheumatoid Arthritis and the Risk of Serious Infections and Malignancies: Systematic Review and Meta-Analysis of Rare Harmful Effects in Randomized Controlled Trials. <i>JAMA</i>. 2006;295(19):2275-2285.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/16705109/pubmed" id="16705109" target="_blank">16705109</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34172516">
<a name="34172516"></a>Brahmer JR, Abu-Sbeih H, Ascierto PA, et al. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events. <i>J Immunother Cancer</i>. 2021;9(6):e002435. doi:10.1136/jitc-2021-002435<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/34172516/pubmed" id="34172516" target="_blank">34172516</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16188920">
<a name="16188920"></a>Brooklyn TN, Dunnill MG, Shetty A, et al. Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial. <i>Gut</i>. 2006;55(4):505-509.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/16188920/pubmed" id="16188920" target="_blank">16188920</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27981215">
<a name="27981215"></a>Bryant KD, DeNunzio MJ, Ford MJ. Linear IgA dermatosis after infliximab infusion for ulcerative colitis. <i>JAAD Case Rep</i>. 2016;2(6):448-450.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/27981215/pubmed" id="27981215" target="_blank">27981215</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16352636">
<a name="16352636"></a>Buch MH, Bryer D, Lindsay S, et al. Shortening Infusion Times for Infliximab Administration. <i>Rheumatology (Oxford)</i>. 2006;45(4):485-486.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/16352636/pubmed" id="16352636" target="_blank">16352636</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18672254">
<a name="18672254"></a>Burns JC, Best BM, Mejias A, et al. Infliximab treatment of intravenous immunoglobulin-resistant Kawasaki disease. <i>J Pediatr</i>. 2008;153(6):833-838.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/18672254/pubmed" id="18672254" target="_blank">18672254</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15870671">
<a name="15870671"></a>Burns JC, Mason WH, Hauger SB, et al. Infliximab treatment for refractory Kawasaki syndrome. <i>J Pediatr</i>. 2005;146(5):662-667.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/15870671/pubmed" id="15870671" target="_blank">15870671</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34715057">
<a name="34715057"></a>Burns JC, Roberts SC, Tremoulet AH, et al. Infliximab versus second intravenous immunoglobulin for treatment of resistant Kawasaki disease in the USA (KIDCARE): a randomised, multicentre comparative effectiveness trial. <i>Lancet Child Adolesc Health</i>. 2021;5(12):852-861. doi:10.1016/S2352-4642(21)00270-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/34715057/pubmed" id="34715057" target="_blank">34715057</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19370307">
<a name="19370307"></a>Carlsen KM, Riis L, Madsen OR. Toxic hepatitis induced by infliximab in a patient with rheumatoid arthritis with no relapse after switching to etanercept. <i>Clin Rheumatol</i>. 2009;28(8):1001-1003. doi:10.1007/s10067-009-1179-y<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/19370307/pubmed" id="19370307" target="_blank">19370307</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12603689">
<a name="12603689"></a>Carpenter PA and Sanders JE. Steroid-refractory graft-vs-host disease: past, present and future. <i>Pediatr Transplant.</i> 2003;7(suppl 3):19-31.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/12603689/pubmed" id="12603689" target="_blank">12603689</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6423951">
<a name="6423951"></a>Centers for Disease Control (CDC). Unusual syndrome with fatalities among premature infants: association with a new intravenous vitamin E product.<i> MMWR Morb Mortal Wkly Rep</i>. 1984;33(14):198-199.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/6423951/pubmed" id="6423951" target="_blank">6423951</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-CDC.1">
<a name="CDC.1"></a>Centers for Disease Control. Testing and Treatment of Latent Tuberculosis Infection. <i>MMWR Recomm Rep</i>. 2000;49(RR-6).</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24935270">
<a name="24935270"></a>Chalasani NP, Hayashi PH, Bonkovsky HL, et al. ACG clinical guideline: the diagnosis and management of idiosyncratic drug-induced liver injury. <i>Am J Gastroenterol</i>. 2014;109(7):950-966.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/24935270/pubmed" id="24935270" target="_blank">24935270</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30311152">
<a name="30311152"></a>Checkley LA, Kristofek L, Kile S, Bolgar W. Incidence and management of infusion reactions to infliximab in an alternate care setting. <i>Dig Dis Sci</i>. 2019;64(3):855-862. doi:10.1007/s10620-018-5319-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/30311152/pubmed" id="30311152" target="_blank">30311152</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34496051">
<a name="34496051"></a>Chen HK, Shao SC, Weng MY, et al. Risk of heart failure in rheumatoid arthritis patients treated with tumor necrosis factor-α Inhibitors. <i>Clin Pharmacol Ther</i>. 2021;110(6):1595-1603. doi:10.1002/cpt.2415<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/34496051/pubmed" id="34496051" target="_blank">34496051</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26032391">
<a name="26032391"></a>Cheng FK, Bridges EE, Betteridge JD. Drug-induced liver injury from initial dose of infliximab. <i>Mil Med</i>. 2015;180(6):e723-e724. doi:10.7205/MILMED-D-14-00485<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/26032391/pubmed" id="26032391" target="_blank">26032391</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33747126">
<a name="33747126"></a>Choi SJ, Ahn SM, Oh JS, et al. Anti-tumor necrosis factor-induced lupus in patients with inflammatory bowel disease: a hospital-based cohort study from Korea. <i>Therap Adv Gastroenterol</i>. 2021;14:1756284821997794. doi:10.1177/1756284821997794<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/33747126/pubmed" id="33747126" target="_blank">33747126</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12796126">
<a name="12796126"></a>Chung ES, Packer M, Lo KH, et al. Randomized, Double-Blind, Placebo-Controlled, Pilot Trial of Infliximab, a Chimeric Monoclonal Antibody to Tumor Necrosis Factor-Alpha, in Patients with Moderate-to-Severe Heart Failure: Results of the Anti-TNF Therapy Against Congestive Heart Failure (ATTACH) Trial. <i>Circulation</i>. 2003;107(25):3133-3140.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/12796126/pubmed" id="12796126" target="_blank">12796126</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33013843">
<a name="33013843"></a>Clements T, Rice TF, Vamvakas G, et al. Update on transplacental transfer of IgG subclasses: impact of maternal and fetal factors. <i>Front Immunol.</i> 2020;11:1920. doi:10.3389/fimmu.2020.01920<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/33013843/pubmed" id="33013843" target="_blank">33013843</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26641955">
<a name="26641955"></a>Cleynen I, Van Moerkercke W, Billiet T, et al. Characteristics of skin lesions associated with anti-tumor necrosis factor therapy in patients with inflammatory bowel disease: a cohort study. <i>Ann Intern Med</i>. 2016 Jan 5;164(1):10-22. doi:10.7326/M15-0729<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/26641955/pubmed" id="26641955" target="_blank">26641955</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34548377">
<a name="34548377"></a>Cole LD, Osborne CM, Silveira LJ, et al. IVIG compared to IVIG plus infliximab in multisystem inflammatory syndrome in children. <i>Pediatrics</i>. Published online September 21, 2021. doi:10.1542/peds.2021-052702<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/34548377/pubmed" id="34548377" target="_blank">34548377</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30289537">
<a name="30289537"></a>Conti F, Atzeni F, Massaro L, et al. The influence of comorbidities on the efficacy of tumour necrosis factor inhibitors, and the effect of tumour necrosis factor inhibitors on comorbidities in rheumatoid arthritis: report from a National Consensus Conference. <i>Rheumatology (Oxford)</i>. 2018;57(Suppl 7):vii11-vii22. doi:10.1093/rheumatology/key209<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/30289537/pubmed" id="30289537" target="_blank">30289537</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32527153">
<a name="32527153"></a>Cossio ML, Genois A, Jantchou P, Hatami A, Deslandres C, McCuaig C. Skin manifestations in pediatric patients treated with a TNF-alpha inhibitor for inflammatory bowel disease: a retrospective study [formula: see text].<i> J Cutan Med Surg</i>. 2020;24(4):333-339. doi:10.1177/1203475420917387<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/32527153/pubmed" id="32527153" target="_blank">32527153</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15069017">
<a name="15069017"></a>Couriel D, Saliba R, Hicks K, et al. Tumor Necrosis Factor-Alpha Blockade for the Treatment of Acute GVHD. <i>Blood</i>. 2004;104(3):649-654.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/15069017/pubmed" id="15069017" target="_blank">15069017</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12492735">
<a name="12492735"></a>Crandall WV, Mackner LM. Infusion Reactions to Infliximab in Children and Adolescents: Frequency, Outcome and a Predictive Model. <i>Aliment Pharmacol Ther</i>. 2003;17(1):75-84.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/12492735/pubmed" id="12492735" target="_blank">12492735</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24093840">
<a name="24093840"></a>Crowson CS, Liao KP, Davis JM 3rd, et al. Rheumatoid arthritis and cardiovascular disease. <i>Am Heart J</i>. 2013;166(4):622-628.e1. doi:10.1016/j.ahj.2013.07.010<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/24093840/pubmed" id="24093840" target="_blank">24093840</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18050253">
<a name="18050253"></a>Curtis JR, Xi J, Patkar N, Xie A, Saag KG, Martin C. Drug-specific and time-dependent risks of bacterial infection among patients with rheumatoid arthritis who were exposed to tumor necrosis factor alpha antagonists. <i>Arthritis Rheum</i>. 2007;56(12):4226-4227. doi:10.1002/art.23050<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/18050253/pubmed" id="18050253" target="_blank">18050253</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34402108">
<a name="34402108"></a>Cyrenne BM, Parpia AS, Sibbald C. Paradoxical psoriasis in pediatric patients: a systematic review. <i>Pediatr Dermatol</i>. 2021;38(5):1086-1093. doi:10.1111/pde.14712<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/34402108/pubmed" id="34402108" target="_blank">34402108</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28218339">
<a name="28218339"></a>Darrigade AS, Milpied B, Truchetet ME, et al. Pattern and severity of psoriasiform eruptions in patients with inflammatory bowel diseases, arthritis or skin inflammatory disorders treated with TNF-alpha inhibitors. <i>Acta Derm Venereol</i>. 2017;97(6):731-734. doi: 0.2340/00015555-2636<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/28218339/pubmed" id="28218339" target="_blank">28218339</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24267475">
<a name="24267475"></a>Dassopoulos T, Sultan S, Falck-Ytter YT, et al. American Gastroenterological Association Institute technical review on the use of thiopurines, methotrexate, and anti-TNF-α biologic drugs for the induction and maintenance of remission in inflammatory Crohn's disease. <i>Gastroenterology</i>. 2013;145(6):1464-1478.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/24267475/pubmed" id="24267475" target="_blank">24267475</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28657923">
<a name="28657923"></a>deBruyn JC, Jacobson K, El-Matary W, et al. Long-term outcomes of infliximab use for pediatric Crohn disease: a Canadian multicenter clinical practice experience. <i>J Pediatr Gastroenterol Nutr</i>. 2018;66(2):268-273. doi:10.1097/MPG.0000000000001672<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/28657923/pubmed" id="28657923" target="_blank">28657923</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30657070">
<a name="30657070"></a>de Carvalho JF, dos Santos MNP, de Oliveira JMV, Silva ANSL, de Araujo RPC, Cardozo JB. Evaluation of the safety and satisfaction of rheumatic patients with accelerated infliximab infusion. <i>Adv in Rheumatol</i>. 2018;58(22):1-3.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/30657070/pubmed" id="30657070" target="_blank">30657070</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22960136">
<a name="22960136"></a>Denadai R, Teixeira FV, Steinwurz F, Romiti R, Saad-Hossne R. Induction or exacerbation of psoriatic lesions during anti-TNF-α therapy for inflammatory bowel disease: a systematic literature review based on 222 cases. <i>J Crohns Colitis</i>. 2013;7(7):517-524. doi:10.1016/j.crohns.2012.08.007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/22960136/pubmed" id="22960136" target="_blank">22960136</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33370961">
<a name="33370961"></a>Dermawan A, So K, Venugopal K, Picardo S. Infliximab-induced optic neuritis. <i>BMJ Case Rep</i>. 2020;13(12):e236041. doi:10.1136/bcr-2020-236041<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/33370961/pubmed" id="33370961" target="_blank">33370961</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10764337">
<a name="10764337"></a>Diagnostic Standards and Classification of Tuberculosis in Adults and Children. Official Statement of the American Thoracic Society and the Centers for Disease Control and Prevention. <i>Am J Respir Crit Care Med</i>. 2000;161:1376-1395.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/10764337/pubmed" id="10764337" target="_blank">10764337</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19845719">
<a name="19845719"></a>Dommasch E, Gelfand JM. Is There Truly a Risk of Lymphoma From Biologic Therapies? <i>Dermatol Ther</i>. 2009;22(5):418-430.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/19845719/pubmed" id="19845719" target="_blank">19845719</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25078637">
<a name="25078637"></a>Drent M, Cremers JP, Jansen TL, Baughman RP. Practical eminence and experience-based recommendations for use of TNF-α inhibitors in sarcoidosis. <i>Sarcoidosis Vasc Diffuse Lung Dis.</i> 2014;31(2):91-107.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/25078637/pubmed" id="25078637" target="_blank">25078637</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28211161">
<a name="28211161"></a>Eickstaedt JB, Killpack L, Tung J, Davis D, Hand JL, Tollefson MM. Psoriasis and psoriasiform eruptions in pediatric patients with inflammatory bowel disease treated with anti-tumor necrosis factor alpha agents. <i>Pediatr Dermatol</i>. 2017;34(3):253-260. doi:10.1111/pde.13081<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/28211161/pubmed" id="28211161" target="_blank">28211161</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10843670">
<a name="10843670"></a>Eissner G, Kirchner S, Lindner H, et al. Reverse signaling through transmembrane TNF confers resistance to lipopolysaccharide in human monocytes and macrophages. <i>J Immunol</i>. 2000;164(12):6193-6198. doi:10.4049/jimmunol.164.12.6193<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/10843670/pubmed" id="10843670" target="_blank">10843670</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35273881">
<a name="35273881"></a>Eiswerth MJ, Heckroth MA, Ismail A, Gondim DD, Kaufman R. Infliximab-induced vanishing bile duct syndrome. <i>Cureus</i>. 2022;14(2):e21940. doi:10.7759/cureus.21940<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/35273881/pubmed" id="35273881" target="_blank">35273881</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOH">
<a name="Expert.DOH"></a>Expert opinion. Senior Hepatic Editorial Team: Matt Harris, PharmD, MHS, BCPS, FAST; Jeong Park, PharmD, MS, BCTXP, FCCP, FAST; Arun Jesudian, MD; Sasan Sakiani, MD.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26965410">
<a name="26965410"></a>Faivre C, Villani AP, Aubin F, et al. Hidradenitis suppurativa (HS): an unrecognized paradoxical effect of biologic agents (BA) used in chronic inflammatory diseases. <i>J Am Acad Dermatol</i>. 2016;74(6):1153-1159. doi:10.1016/j.jaad.2016.01.018<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/26965410/pubmed" id="26965410" target="_blank">26965410</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25110258">
<a name="25110258"></a>Feuerstein JD, Cheifetz AS. Miscellaneous adverse events with biologic agents (excludes infection and malignancy). <i>Gastroenterol Clin North Am</i>. 2014;43(3):543-563. doi:10.1016/j.gtc.2014.05.002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/25110258/pubmed" id="25110258" target="_blank">25110258</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34051983">
<a name="34051983"></a>Feuerstein JD, Ho EY, Shmidt E, et al; American Gastroenterological Association Institute Clinical Guidelines Committee. AGA clinical practice guidelines on the medical management of moderate to severe luminal and perianal fistulizing Crohn's disease. <i>Gastroenterology</i>. 2021;160(7):2496-2508. doi:10.1053/j.gastro.2021.04.022<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/34051983/pubmed" id="34051983" target="_blank">34051983</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31945371">
<a name="31945371"></a>Feuerstein JD, Isaacs KL, Schneider Y, Siddique SM, Falck-Ytter Y, Singh S; AGA Institute Clinical Guidelines Committee. AGA clinical practice guidelines on the management of moderate to severe ulcerative colitis. <i>Gastroenterology</i>. 2020;158(5):1450-1461. doi:10.1053/j.gastro.2020.01.006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/31945371/pubmed" id="31945371" target="_blank">31945371</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28780013">
<a name="28780013"></a>Feuerstein JD, Nguyen GC, Kupfer SS, Falck-Ytter Y, Singh S; American Gastroenterological Association Institute Clinical Guidelines Committee. American Gastroenterological Association Institute guideline on therapeutic drug monitoring in inflammatory bowel disease. <i>Gastroenterology.</i> 2017;153(3):827-834. doi:10.1053/j.gastro.2017.07.032<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/28780013/pubmed" id="28780013" target="_blank">28780013</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34101387">
<a name="34101387"></a>Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. <i>Arthritis Care Res (Hoboken)</i>. 2021;73(7):924-939. doi:10.1002/acr.24596<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/34101387/pubmed" id="34101387" target="_blank">34101387</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26195181">
<a name="26195181"></a>Fréling E, Baumann C, Cuny JF, et al. Cumulative incidence of, risk factors for, and outcome of dermatological complications of anti-TNF therapy in inflammatory bowel disease: a 14-year experience. <i>Am J Gastroenterol</i>. 2015a;110(8):1186-116. doi:10.1038/ajg.2015.205<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/26195181/pubmed" id="26195181" target="_blank">26195181</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26181108">
<a name="26181108"></a>Fréling E, Peyrin-Biroulet L, Poreaux C, et al. IgE antibodies and skin tests in immediate hypersensitivity reactions to infliximab in inflammatory bowel disease: impact on infliximab retreatment. <i>Eur J Gastroenterol Hepatol</i>. 2015b;27(10):1200-1208. doi:10.1097/MEG.0000000000000436<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/26181108/pubmed" id="26181108" target="_blank">26181108</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26692395">
<a name="26692395"></a>French JB, Bonacini M, Ghabril M, Foureau D, Bonkovsky HL. Hepatotoxicity associated with the use of anti-TNF-α agents. <i>Drug Saf</i>. 2016;39(3):199-208. doi:10.1007/s40264-015-0366-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/26692395/pubmed" id="26692395" target="_blank">26692395</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22858514">
<a name="22858514"></a>Fritzsche J, Pilch A, Mury D, Schaefer C, Weber-Schoendorfer C. Infliximab and adalimumab use during breastfeeding. <i>J Clin Gastroenterol</i>. 2012;46(8):718-719.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/22858514/pubmed" id="22858514" target="_blank">22858514</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16434333">
<a name="16434333"></a>Gamarra RM, McGraw SD, Drelichman VS, Maas LC. Serum sickness-like reactions in patients receiving intravenous infliximab. <i>J Emerg Med</i>. 2006;30(1):41-44. doi:10.1016/j.jemermed.2005.01.033<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/16434333/pubmed" id="16434333" target="_blank">16434333</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16550301">
<a name="16550301"></a>García Aparicio AM, Rey JR, Sanz AH, Alvarez JS. Successful treatment with etanercept in a patient with hepatotoxicity closely related to infliximab. <i>Clin Rheumatol</i>. 2007;26(5):811-813. doi:10.1007/s10067-006-0253-y<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/16550301/pubmed" id="16550301" target="_blank">16550301</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31677004">
<a name="31677004"></a>Geldhof A, Slater J, Clark M, Chandran U, Coppola D. Exposure to infliximab during pregnancy: post-marketing experience. <i>Drug Saf</i>. 2020;43(2):147-161. doi:10.1007/s40264-019-00881-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/31677004/pubmed" id="31677004" target="_blank">31677004</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23333219">
<a name="23333219"></a>Ghabril M, Bonkovsky HL, Kum C, et al. Liver injury from tumor necrosis factor-α antagonists: analysis of thirty-four cases. <i>Clin Gastroenterol Hepatol</i>. 2013;11(5):558-564.e3. doi:10.1016/j.cgh.2012.12.025<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/23333219/pubmed" id="23333219" target="_blank">23333219</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34493490">
<a name="34493490"></a>Ghalandari N, Kemper E, Crijns IH, et al. Analysing cord blood levels of TNF inhibitors to validate the EULAR points to consider for TNF inhibitor use during pregnancy. <i>Ann Rheum Dis</i>. 2022;81(3):402-405. doi:10.1136/annrheumdis-2021-221036<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/34493490/pubmed" id="34493490" target="_blank">34493490</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19560226">
<a name="19560226"></a>Gisondi P, Targher G, Zoppini G, Girolomoni G. Non-alcoholic fatty liver disease in patients with chronic plaque psoriasis. <i>J Hepatol</i>. 2009;51(4):758-764. doi:10.1016/j.jhep.2009.04.020<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/19560226/pubmed" id="19560226" target="_blank">19560226</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31731980">
<a name="31731980"></a>Godfrey MS, Friedman LN. Tuberculosis and biologic therapies: anti-tumor necrosis factor-α and beyond. <i>Clin Chest Med</i>. 2019;40(4):721-739. doi:10.1016/j.ccm.2019.07.003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/31731980/pubmed" id="31731980" target="_blank">31731980</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35718887">
<a name="35718887"></a>Goodman SM, Springer BD, Chen AF, et al. 2022 American College of Rheumatology/American Association of Hip and Knee Surgeons guideline for the perioperative management of antirheumatic medication in patients with rheumatic diseases undergoing elective total hip or total knee arthroplasty. <i>Arthritis Care Res (Hoboken)</i>. 2022;74(9):1399-1408. doi:10.1002/acr.24893<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/35718887/pubmed" id="35718887" target="_blank">35718887</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35258557">
<a name="35258557"></a>Goulden B, Chua N, Parker E, Giles I. A systematic review of live vaccine outcomes in infants exposed to biologic disease modifying anti-rheumatic drugs in utero. <i>Rheumatology (Oxford)</i>. 2022;61(10):3902-3906. doi:10.1093/rheumatology/keac141<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/35258557/pubmed" id="35258557" target="_blank">35258557</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22056398">
<a name="22056398"></a>Grijalva CG, Chen L, Delzell E, et al. Initiation of tumor necrosis factor-α antagonists and the risk of hospitalization for infection in patients with autoimmune diseases. <i>JAMA</i>. 2011;306(21):2331-2339. doi:10.1001/jama.2011.1692<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/22056398/pubmed" id="22056398" target="_blank">22056398</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24090905">
<a name="24090905"></a>Grosen A, Julsgaard M, Kelsen J, Christensen LA. Infliximab concentrations in the milk of nursing mothers with inflammatory bowel disease. <i>J Crohns Colitis</i>. 2014;8(2):175-176.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/24090905/pubmed" id="24090905" target="_blank">24090905</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25266439">
<a name="25266439"></a>Guiddir T, Frémond ML, Triki TB, et al. Anti-TNF-α therapy may cause neonatal neutropenia. <i>Pediatrics</i>. 2014;134(4):e1189-e1193.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/25266439/pubmed" id="25266439" target="_blank">25266439</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33105057">
<a name="33105057"></a>Hammam N, Evans M, Morgan E, et al. Treatment of sarcoidosis in US rheumatology practices: data from the American College of Rheumatology's Rheumatology Informatics System for Effectiveness (RISE) Registry. <i>Arthritis Care Res (Hoboken)</i>. 2022;74(3):371-376. doi:10.1002/acr.24496<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/33105057/pubmed" id="33105057" target="_blank">33105057</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20848473">
<a name="20848473"></a>Hamzaoglu H, Cooper J, Alsahli M, Falchuk KR, Peppercorn MA, Farrell RJ. Safety of infliximab in Crohn's disease: a large single-center experience. <i>Inflamm Bowel Dis</i>. 2010;16(12):2109-2116. doi:10.1002/ibd.21290<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/20848473/pubmed" id="20848473" target="_blank">20848473</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16981296">
<a name="16981296"></a>Han C, Robinson DW Jr, Hackett MV, Paramore LC, Fraeman KH, Bala MV. Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. <i>J Rheumatol</i>. 2006;33(11):2167-2172<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/16981296/pubmed" id="16981296" target="_blank">16981296</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22515220">
<a name="22515220"></a>Hawryluk EB, Linskey KR, Duncan LM, Nazarian RM. Broad range of adverse cutaneous eruptions in patients on TNF-alpha antagonists. <i>J Cutan Pathol</i>. 2012;39(5):481-492. doi:10.1111/j.1600-0560.2012.01894.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/22515220/pubmed" id="22515220" target="_blank">22515220</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35118829">
<a name="35118829"></a>Henderson LA, Canna SW, Friedman KG, et al. American College of Rheumatology (ACR) clinical guidance for multisystem inflammatory syndrome in children associated with SARS-CoV-2 and hyperinflammation in pediatric COVID-19: Version 3. <i>Arthritis Rheumatol</i>. Published online February 3, 2022. doi:10.1002/art.42062<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/35118829/pubmed" id="35118829" target="_blank">35118829</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9345421">
<a name="9345421"></a>Hohlfeld R. Inhibitors of tumor necrosis factor-alpha: promising agents for the treatment of multiple sclerosis? <i>Mult Scler</i>. 1996;1(6):376-378. doi:10.1177/135245859600100619<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/9345421/pubmed" id="9345421" target="_blank">9345421</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26768759">
<a name="26768759"></a>Her M, Kavanaugh A. Alterations in immune function with biologic therapies for autoimmune disease. <i>J Allergy Clin Immunol</i>. 2016;137(1):19-27. doi:10.1016/j.jaci.2015.10.023<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/26768759/pubmed" id="26768759" target="_blank">26768759</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33945946">
<a name="33945946"></a>Hutto SK, Rice DR, Mateen FJ. CNS demyelination with TNFα inhibitor exposure: a retrospective cohort study. <i>J Neuroimmunol</i>. 2021;356:577587. doi:10.1016/j.jneuroim.2021.577587<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/33945946/pubmed" id="33945946" target="_blank">33945946</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Inflectra.1">
<a name="Inflectra.1"></a>Inflectra (infliximab-dyyb) [prescribing information]. New York, NY: Pfizer; May 2023.</div>
</li>
<li>
<div class="reference">
                  Inflectra (infliximab) [product monograph]. Kirkland, Quebec, Canada: Pfizer Canada ULC; July 2020.</div>
</li>
<li>
<div class="reference">
                  Infliximab injection [prescribing information]. Horsham, PA: Janssen Biotech Inc; October 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31643528">
<a name="31643528"></a>Infliximab. In: <i>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury</i>. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; February 10, 2017.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/31643528/pubmed" id="31643528" target="_blank">31643528</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12534540">
<a name="12534540"></a>Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension. <i>Contact Dermatitis</i>. 2002;47(5):312-313.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/12534540/pubmed" id="12534540" target="_blank">12534540</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Ixifi (infliximab-qbtx) [prescribing information]. New York, NY: Pfizer; December 2017.</div>
</li>
<li>
<div class="reference">
                  Ixifi (infliximab-qbtx) [prescribing information]. New York, NY: Pfizer; January 2020.</div>
</li>
<li>
<div class="reference">
                  Ixifi (infliximab) [product monograph]. Kirkland, Quebec, Canada: Pfizer Canada ULC; December 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33384335">
<a name="33384335"></a>Jongsma MME, Aardoom MA, Cozijnsen MA, et al. First-line treatment with infliximab versus conventional treatment in children with newly diagnosed moderate-to-severe Crohn's disease: an open-label multicentre randomised controlled trial. <i>Gut</i>. 2022;71(1):34-42. doi:10.1136/gutjnl-2020-322339<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/33384335/pubmed" id="33384335" target="_blank">33384335</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30305177">
<a name="30305177"></a>Johnson DH, Zobniw CM, Trinh VA, et al. Infliximab associated with faster symptom resolution compared with corticosteroids alone for the management of immune-related enterocolitis. <i>J Immunother Cancer</i>. 2018;6(1):103. doi:10.1186/s40425-018-0412-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/30305177/pubmed" id="30305177" target="_blank">30305177</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23557269">
<a name="23557269"></a>Juhász K, Buzás K, Duda E. Importance of reverse signaling of the TNF superfamily in immune regulation. <i>Expert Rev Clin Immunol</i>. 2013;9(4):335-348. doi:10.1586/eci.13.14<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/23557269/pubmed" id="23557269" target="_blank">23557269</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27063728">
<a name="27063728"></a>Julsgaard M, Christensen LA, Gibson PR, et al. Concentrations of adalimumab and infliximab in mothers and newborns, and effects on infection. <i>Gastroenterology</i>. 2016;151(1):110-119.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/27063728/pubmed" id="27063728" target="_blank">27063728</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31845616">
<a name="31845616"></a>Kalinowska-Lyszczarz A, Fereidan-Esfahani M, Guo Y, Lucchinetti CF, Tobin WO. Pathological findings in central nervous system demyelination associated with infliximab. <i>Mult Scler</i>. 2020;26(9):1124-1129. doi:10.1177/1352458519894710<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/31845616/pubmed" id="31845616" target="_blank">31845616</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19142167">
<a name="19142167"></a>Kane S, Ford J, Cohen R, Wagner C. Absence of infliximab in infants and breast milk from nursing mothers receiving therapy for Crohn's disease before and after delivery. <i>J Clin Gastroenterol</i>. 2009;43(7):613-616.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/19142167/pubmed" id="19142167" target="_blank">19142167</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33604964">
<a name="33604964"></a>Kantasiripitak W, Verstockt B, Alsoud D, et al. The effect of aging on infliximab exposure and response in patients with inflammatory bowel diseases. <i>Br J Clin Pharmacol</i>. 2021;87(10):3776-3789. doi:10.1111/bcp.14785<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/33604964/pubmed" id="33604964" target="_blank">33604964</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34707687">
<a name="34707687"></a>Kapila N, Gonzalez A, Rosado JM, et al. Safety of anti-TNF agents in patients with compensated cirrhosis: a case-control study. <i>Therap Adv Gastroenterol</i>. 2021;14:17562848211037094. doi:10.1177/17562848211037094<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/34707687/pubmed" id="34707687" target="_blank">34707687</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35700275">
<a name="35700275"></a>Kawamoto A, Fujii T, Mitani R, Suzuki Y, Yauchi T, Okamoto R. Serum levels of infliximab biosimilar in a child delivered from a mother treated for ulcerative colitis. <i>Inflamm Bowel Dis</i>. 2022;28(8):1298-1299. doi:10.1093/ibd/izac111<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/35700275/pubmed" id="35700275" target="_blank">35700275</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25739794">
<a name="25739794"></a>Kelly D, O'Connell O, Henry M. Adalimumab-induced lupus serositis. <i>BMJ Case Rep</i>. 2015;2015:bcr2014207323. doi:10.1136/bcr-2014-207323<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/25739794/pubmed" id="25739794" target="_blank">25739794</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22589260">
<a name="22589260"></a>Kelsall J, Rogers P, Galindo G, De Vera MA. Safety of infliximab treatment in patients with rheumatoid arthritis in a real-world clinical setting: description and evaluation of infusion reactions. <i>J Rheumatol</i>. 2012;39(8):1539-1545. doi:10.3899/jrheum.110956<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/22589260/pubmed" id="22589260" target="_blank">22589260</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28337644">
<a name="28337644"></a>Kemanetzoglou E, Andreadou E. CNS demyelination with TNF-α blockers. <i>Curr Neurol Neurosci Rep</i>. 2017;17(4):36. doi:10.1007/s11910-017-0742-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/28337644/pubmed" id="28337644" target="_blank">28337644</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25473247">
<a name="25473247"></a>Kim HS, You HS, Cho HH, et al. Two cases of generalized pustular psoriasis: successful treatment with infliximab. <i>Ann Dermatol</i>. 2014;26(6):787-788.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/25473247/pubmed" id="25473247" target="_blank">25473247</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20472597">
<a name="20472597"></a>Klarenbeek NB, van der Kooij SM, Huizinga TJ, et al. Blood pressure changes in patients with recent-onset rheumatoid arthritis treated with four different treatment strategies: a post hoc analysis from the BeSt trial. <i>Ann Rheum Dis</i>. 2010;69(7):1342-1345. doi:10.1136/ard.2009.124180<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/20472597/pubmed" id="20472597" target="_blank">20472597</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17655372">
<a name="17655372"></a>Klotz U, Teml A, Schwab M. Clinical Pharmacokinetics and Use of Infliximab. <i>Clin Pharmacokinet</i>, 2007;45(8):645-660.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/17655372/pubmed" id="17655372" target="_blank">17655372</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29564668">
<a name="29564668"></a>Kok B, Lester ELW, Lee WM, et al. Acute liver failure from tumor necrosis factor-α antagonists: report of four cases and literature review. <i>Dig Dis Sci</i>. 2018;63(6):1654-1666. doi:10.1007/s10620-018-5023-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/29564668/pubmed" id="29564668" target="_blank">29564668</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28652663">
<a name="28652663"></a>Koller T, Galambosova M, Filakovska S, et al. Drug-induced liver injury in inflammatory bowel disease: 1-year prospective observational study. <i>World J Gastroenterol</i>. 2017;23(22):4102-4111. doi:10.3748/wjg.v23.i22.4102<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/28652663/pubmed" id="28652663" target="_blank">28652663</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29895751">
<a name="29895751"></a>Kotyla PJ. Bimodal function of anti-TNF treatment: shall we be concerned about anti-TNF treatment in patients with rheumatoid arthritis and heart failure? <i>Int J Mol Sci</i>. 2018;19(6):1739. doi:10.3390/ijms19061739<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/29895751/pubmed" id="29895751" target="_blank">29895751</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30767720">
<a name="30767720"></a>Kumar N, Abboud H. Iatrogenic CNS demyelination in the era of modern biologics. <i>Mult Scler</i>. 2019;25(8):1079-1085. doi:10.1177/1352458519828601<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/30767720/pubmed" id="30767720" target="_blank">30767720</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32421186">
<a name="32421186"></a>Kunchok A, Aksamit AJ Jr, Davis JM 3rd, et al. Association between tumor necrosis factor inhibitor exposure and inflammatory central nervous system events. <i>JAMA Neurol</i>. 2020;77(8):937-946. doi:10.1001/jamaneurol.2020.1162<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/32421186/pubmed" id="32421186" target="_blank">32421186</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Kwon.1">
<a name="Kwon.1"></a>Kwon HJ, Cot TR, Cuffe MS, Kramer JM, Braun MM. Tumor necrosis factor antagonists and heart failure. <i>Annals of Internal Medicine</i>. 2003;138:807-811. Available at https://doi.org/10.7326/0003-4819-138-10-200305200-00004
                     <span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/Kwon.1/pubmed" id="Kwon.1" target="_blank">Kwon.1</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20535789">
<a name="20535789"></a>Lahdenne P, Wikström AM, Aalto K, et al. Prevention of Acute Adverse Events Related to Infliximab Infusions in Pediatric Patients. <i>Arthritis Care Res (Hoboken)</i>. 2010;62(6):785-790.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/20535789/pubmed" id="20535789" target="_blank">20535789</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21358439">
<a name="21358439"></a>Lane MA, McDonald JR, Zeringue AL, et al. TNF-α antagonist use and risk of hospitalization for infection in a national cohort of veterans with rheumatoid arthritis. <i>Medicine (Baltimore)</i>. 2011;90(2):139-145. doi:10.1097/MD.0b013e318211106a<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/21358439/pubmed" id="21358439" target="_blank">21358439</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21719446">
<a name="21719446"></a>Lan JL, Chen YM, Hsieh TY, et al. Kinetics of viral loads and risk of hepatitis B virus reactivation in hepatitis B core antibody-positive rheumatoid arthritis patients undergoing anti-tumour necrosis factor alpha therapy. <i>Ann Rheum Dis</i>. 2011;70(10):1719-1725. doi:10.1136/ard.2010.148783<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/21719446/pubmed" id="21719446" target="_blank">21719446</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34427860">
<a name="34427860"></a>Lau G, Yu ML, Wong G, et al. APASL clinical practice guideline on hepatitis B reactivation related to the use of immunosuppressive therapy. <i>Hepatol Int</i>. 2021;15(5):1031-1048. doi:10.1007/s12072-021-10239-x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/34427860/pubmed" id="34427860" target="_blank">34427860</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17300238">
<a name="17300238"></a>Lee HH, Song IH, Friedrich M, et al. Cutaneous side-effects in patients with rheumatic diseases during application of tumour necrosis factor-alpha antagonists. <i>Br J Dermatol</i>. 2007;156(3):486-491. doi:10.1111/j.1365-2133.2007.07682.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/17300238/pubmed" id="17300238" target="_blank">17300238</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18753157">
<a name="18753157"></a>Leombruno JP, Einarson TR, Keystone EC. The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events. <i>Ann Rheum Dis</i>. 2009;68(7):1136-1145. doi:10.1136/ard.2008.091025<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/18753157/pubmed" id="18753157" target="_blank">18753157</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29610508">
<a name="29610508"></a>Lichtenstein GR, Loftus EV, Isaacs KL, Regueiro MD, Gerson LB, Sands BE. ACG clinical guideline: management of Crohn's disease in adults. <i>Am J Gastroenterol</i>. 2018;113(4):481-517. doi:10.1038/ajg.2018.27<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/29610508/pubmed" id="29610508" target="_blank">29610508</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26092578">
<a name="26092578"></a>Lichtenstein L, Ron Y, Kivity S, et al. Infliximab-related infusion reactions: systematic review. <i>J Crohns Colitis</i>. 2015;9(9):806-815. doi:10.1093/ecco-jcc/jjv096<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/26092578/pubmed" id="26092578" target="_blank">26092578</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31093599">
<a name="31093599"></a>Li SJ, Perez-Chada LM, Merola JF. TNF inhibitor-induced psoriasis: proposed algorithm for treatment and management. <i>J Psoriasis Psoriatic Arthritis</i>. 2019;4(2):70-80. doi:10.1177/2475530318810851<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/31093599/pubmed" id="31093599" target="_blank">31093599</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16255017">
<a name="16255017"></a>Listing J, Strangfeld A, Kary S, et al. Infections in patients with rheumatoid arthritis treated with biologic agents. <i>Arthritis Rheum</i>. 2005;52(11):3403-3412. doi:10.1002/art.21386<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/16255017/pubmed" id="16255017" target="_blank">16255017</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12374238">
<a name="12374238"></a>Ljung T, Staun M, Grove O, Fausa O, Vatn MH, Hellstrom PM. Pyoderma gangrenosum associated with Crohn disease: effect of TNF-alpha blockade with infliximab. <i>Scand J Gastroenterol</i>. 2002;37(9):1108-1110.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/12374238/pubmed" id="12374238" target="_blank">12374238</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28219691">
<a name="28219691"></a>Loomba R, Liang TJ. Hepatitis B reactivation associated with immune suppressive and biological modifier therapies: current concepts, management strategies, and future directions. <i>Gastroenterology</i>. 2017;152(6):1297-1309. doi:10.1053/j.gastro.2017.02.009<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/28219691/pubmed" id="28219691" target="_blank">28219691</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22948700">
<a name="22948700"></a>Lopez-Oilvo MA, Tayar JH, Martinez-Lopez JA, et al. Risk of Malignancies in Patients With Rheumatoid Arthritis Treated With Biologic Therapy: A Meta-Analysis. <i>JAMA</i>. 2012;308(9):898-908.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/22948700/pubmed" id="22948700" target="_blank">22948700</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10985636">
<a name="10985636"></a>Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child. <i>Contact Dermatitis</i>. 2000;43(3):172.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/10985636/pubmed" id="10985636" target="_blank">10985636</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34536074">
<a name="34536074"></a>MacIsaac MB, Julsgaard M, Flanagan E, et al. Anti-TNFα induction therapy for patients with active inflammatory bowel disease during pregnancy: a case series. <i>Inflamm Bowel Dis</i>. 2022;28(4):652-655. doi:10.1093/ibd/izab227<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/34536074/pubmed" id="34536074" target="_blank">34536074</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21162650">
<a name="21162650"></a>Maggi E, Vultaggio A, Matucci A. Acute infusion reactions induced by monoclonal antibody therapy. <i>Expert Rev Clin Immunol</i>. 2011;7(1):55-63. doi:10.1586/eci.10.90<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/21162650/pubmed" id="21162650" target="_blank">21162650</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30948039">
<a name="30948039"></a>Mahadevan U, Robinson C, Bernasko N, et al. Inflammatory bowel disease in pregnancy clinical care pathway: a report from the American Gastroenterological Association IBD Parenthood Project Working Group. <i>Am J Obstet Gynecol</i>. 2019;220(4):308-323.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/30948039/pubmed" id="30948039" target="_blank">30948039</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23200982">
<a name="23200982"></a>Mahadevan U, Wolf DC, Dubinsky M, et al. Placental transfer of anti-tumor necrosis factor agents in pregnant patients with inflammatory bowel disease. <i>Clin Gastroenterol Hepatol</i>. 2013;11(3):286-292.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/23200982/pubmed" id="23200982" target="_blank">23200982</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26422518">
<a name="26422518"></a>Marzano AV, Tavecchio S, Berti E, Gelmetti C, Cugno M. Pustular skin reaction to tumor necrosis factor alpha antagonists in patients with inflammatory bowel diseases. <i>Inflamm Bowel Dis</i>. 2015;21(11):E26-27. doi:10.1097/MIB.0000000000000600<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/26422518/pubmed" id="26422518" target="_blank">26422518</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29857090">
<a name="29857090"></a>Matro R, Martin CF, Wolf D, Shah SA, Mahadevan U. Exposure concentrations of infants breastfed by women receiving biologic therapies for inflammatory bowel diseases and effects of breastfeeding on infections and development. <i>Gastroenterology</i>. 2018;155(3):696-704.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/29857090/pubmed" id="29857090" target="_blank">29857090</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17129817">
<a name="17129817"></a>Mayer L, Young Y. Infusion Reactions and Their Management. <i>Gastroenterol Clin North Am</i>. 2006;35(4):857-866.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/17129817/pubmed" id="17129817" target="_blank">17129817</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23515325">
<a name="23515325"></a>McConnell J, Parvulescu-Codrea S, Behm B, et al. Accelerated infliximab infusions for inflammatory bowel disease improve effectiveness. <i>World J Gastrointest Pharmacol Ther</i>. 2012;3(5):74-82. doi:10.4292/wjgpt.v3.i5.74<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/23515325/pubmed" id="23515325" target="_blank">23515325</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28356445">
<a name="28356445"></a>McCrindle BW, Rowley AH, Newburger JW, et al. Diagnosis, treatment, and long-term management of Kawasaki Disease: a scientific statement for health professionals from the American Heart Association. <i>Circulation</i>. 2017;135(17):e927-e999.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/28356445/pubmed" id="28356445" target="_blank">28356445</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17448012">
<a name="17448012"></a>Meiss F, Helmbold P, Meykadeh N, Gaber G, Marsch WCh, Fischer M. Overlap of acute generalized exanthematous pustulosis and toxic epidermal necrolysis: response to antitumour necrosis factor-alpha antibody infliximab: report of three cases. <i>J Eur Acad Dermatol Venereol</i>. 2007;21(5):717-719. doi:10.1111/j.1468-3083.2006.02026.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/17448012/pubmed" id="17448012" target="_blank">17448012</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34143362">
<a name="34143362"></a>Melani AS, Bigliazzi C, Cimmino FA, Bergantini L, Bargagli E. A comprehensive review of sarcoidosis treatment for pulmonologists. <i>Pulm Ther.</i> 2021;7(2):325-344. doi:10.1007/s41030-021-00160-x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/34143362/pubmed" id="34143362" target="_blank">34143362</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30028008">
<a name="30028008"></a>Melo FJ, Magina S. Clinical management of anti-TNF-alpha-induced psoriasis or psoriasiform lesions in inflammatory bowel disease patients: a systematic review. <i>Int J Dermatol</i>. 2018;57(12):1521-1532. doi:10.1111/ijd.14072<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/30028008/pubmed" id="30028008" target="_blank">30028008</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30772098">
<a name="30772098"></a>Menter A, Strober BE, Kaplan DH, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. <i>J Am Acad Dermatol</i>. 2019;80(4):1029-1072. doi:10.1016/j.jaad.2018.11.057<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/30772098/pubmed" id="30772098" target="_blank">30772098</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24685910">
<a name="24685910"></a>Mercer LK, Lunt M, Low AL, et al. Risk of solid cancer in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. <i>Ann Rheum Dis</i>. 2015;74(6):1087-1093. doi:10.1136/annrheumdis-2013-204851<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/24685910/pubmed" id="24685910" target="_blank">24685910</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21122513">
<a name="21122513"></a>Miehsler W, Novacek G, Wenzl H, et al; Austrian Society of Gastroenterology and Hepatology. A decade of infliximab: the Austrian evidence based consensus on the safe use of infliximab in inflammatory bowel disease. <i>J Crohns Colitis</i>. 2010;4(3):221-256. doi:10.1016/j.crohns.2009.12.001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/21122513/pubmed" id="21122513" target="_blank">21122513</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11762947">
<a name="11762947"></a>Mohan N, Edwards ET, Cupps TR, et al. Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. <i>Arthritis Rheum</i>. 2001;44(12):2862-2869. doi:10.1002/1529-0131(200112)44:12&lt;2862::aid-art474&gt;3.0.co;2-w<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/11762947/pubmed" id="11762947" target="_blank">11762947</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34625145">
<a name="34625145"></a>Montolio Chiva L, Martínez Ferrer À, Mateu Puchades A, Campos Fernández C, Narváez Garcia J, Alegre Sancho JJ. Psoriasis induced by biological therapy. <i>Reumatol Clin (Engl Ed)</i>. 2021;17(8):437-439. doi:10.1016/j.reumae.2020.06.003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/34625145/pubmed" id="34625145" target="_blank">34625145</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19628303">
<a name="19628303"></a>Moustou AE, Matekovits A, Dessinioti C, Antoniou C, Sfikakis PP, Stratigos AJ. Cutaneous side effects of anti-tumor necrosis factor biologic therapy: a clinical review. <i>J Am Acad Dermatol</i>. 2009;61(3):486-504. doi:10.1016/j.jaad.2008.10.060<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/19628303/pubmed" id="19628303" target="_blank">19628303</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21216812">
<a name="21216812"></a>Myasoedova E, Crowson CS, Kremers HM, et al. Lipid paradox in rheumatoid arthritis: the impact of serum lipid measures and systemic inflammation on the risk of cardiovascular disease. <i>Ann Rheum Dis</i>. 2011;70(3):482-487. doi:10.1136/ard.2010.135871<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/21216812/pubmed" id="21216812" target="_blank">21216812</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34292215">
<a name="34292215"></a>Nassar-Sheikh Rashid A, Schonenberg-Meinema D, Berends SE, van den Berg JM, Mathôt RAA. Population pharmacokinetics of infliximab in children with juvenile idiopathic arthritis. <i>Ther Drug Monit</i>. 2022;44(2):301-307. doi:10.1097/FTD.0000000000000914<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/34292215/pubmed" id="34292215" target="_blank">34292215</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NIH.2">
<a name="NIH.2"></a>National Institutes of Health (NIH). COVID-19 Treatment Guidelines Panel. Coronavirus disease 2019 (COVID-19) treatment guideline. <a href="https://www.covid19treatmentguidelines.nih.gov/" target="_blank">https://www.covid19treatmentguidelines.nih.gov/</a>. Updated October 13, 2023. Accessed October 16, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NIH.1">
<a name="NIH.1"></a>National Institutes of Health (NIH). COVID-19 Treatment Guidelines Panel. Therapeutic management of hospitalized pediatric patients with multisystem inflammatory syndrome in children (MIS-C) (with discussion on multisystem inflammatory syndrome in adults [MIS-A]). <a href="https://www.covid19treatmentguidelines.nih.gov/management/clinical-management/hospitalized-pediatric-patients--therapeutic-management-of-mis-c/" target="_blank">https://www.covid19treatmentguidelines.nih.gov/management/clinical-management/hospitalized-pediatric-patients--therapeutic-management-of-mis-c/</a>. Updated February 24, 2022. Accessed March 7, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25609412">
<a name="25609412"></a>Navarro-Millán I, Yang S, DuVall SL, et al. Association of hyperlipidaemia, inflammation and serological status and coronary heart disease among patients with rheumatoid arthritis: data from the National Veterans Health Administration. <i>Ann Rheum Dis</i>. 2016;75(2):341-347. doi:10.1136/annrheumdis-2013-204987<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/25609412/pubmed" id="25609412" target="_blank">25609412</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31290151">
<a name="31290151"></a>Neves JM, Cunha N, Lencastre A, Cabete J. Paradoxical hidradenitis suppurativa to biologic agents: a case series and literature review. <i>Int J Dermatol</i>. 2019;58(11):e226-e228. doi:10.1111/ijd.14585<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/31290151/pubmed" id="31290151" target="_blank">31290151</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27840074">
<a name="27840074"></a>Nguyen GC, Loftus EV Jr, Hirano I, et al; AGA Institute Clinical Guidelines Committee. American Gastroenterological Association Institute guideline on the management of Crohn's disease after surgical resection. <i>Gastroenterology</i>. 2017;152(1):271-275. doi:10.1053/j.gastro.2016.10.038<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/27840074/pubmed" id="27840074" target="_blank">27840074</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15692992">
<a name="15692992"></a>Nicola PJ, Maradit-Kremers H, Roger VL, et al. The risk of congestive heart failure in rheumatoid arthritis: a population-based study over 46 years. <i>Arthritis Rheum</i>. 2005;52(2):412-420. doi:10.1002/art.20855<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/15692992/pubmed" id="15692992" target="_blank">15692992</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-37428480">
<a name="37428480"></a>O'Halloran JA, Ko ER, Anstrom KJ, et al; ACTIV-1 IM Study Group Members. Abatacept, cenicriviroc, or infliximab for treatment of adults hospitalized with COVID-19 pneumonia: a randomized clinical trial. <i>JAMA</i>. 2023;330(4):328-339. doi:10.1001/jama.2023.11043<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/37428480/pubmed" id="37428480" target="_blank">37428480</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24280879">
<a name="24280879"></a>O'Meara S, Nanda KS, Moss AC. Antibodies to infliximab and risk of infusion reactions in patients with inflammatory bowel disease: a systematic review and meta-analysis. <i>Inflamm Bowel Dis</i>. 2014;20(1):1-6. doi:10.1097/01.MIB.0000436951.80898.6d<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/24280879/pubmed" id="24280879" target="_blank">24280879</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27400984">
<a name="27400984"></a>Page RL 2nd, O'Bryant CL, Cheng D, et al; American Heart Association Clinical Pharmacology and Heart Failure and Transplantation Committees of the Council on Clinical Cardiology; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular and Stroke Nursing; and Council on Quality of Care and Outcomes Research. Drugs That May Cause or Exacerbate Heart Failure: A Scientific Statement From the American Heart Association. <i>Circulation</i>. 2016;134(6):e32-e69.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/27400984/pubmed" id="27400984" target="_blank">27400984</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22235228">
<a name="22235228"></a>Palmeira P, Quinello C, Silveira-Lessa AL, Zago CA, Carneiro-Sampaio M. IgG placental transfer in healthy and pathological pregnancies. <i>Clin Dev Immunol</i>. 2012;2012:985646.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/22235228/pubmed" id="22235228" target="_blank">22235228</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24512909">
<a name="24512909"></a>Panaccione R, Ghosh S, Middleton S, et al. Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. <i>Gastroenterology</i>. 2014;146(2):392-400.e3. doi:10.1053/j.gastro.2013.10.052<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/24512909/pubmed" id="24512909" target="_blank">24512909</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17036404">
<a name="17036404"></a>Panteris V, Perdiou A, Tsirimpis V, Karamanolis DG. Acute coronary syndrome after infliximab therapy in a patient with Crohn's disease. <i>World J Gastroenterol</i>. 2006;12(38):6235-6238. doi:10.3748/wjg.v12.i38.6235<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/17036404/pubmed" id="17036404" target="_blank">17036404</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21941193">
<a name="21941193"></a>Parakkal D, Sifuentes H, Semer R, et al. Hepatosplenic T-Cell Lymphoma in Patients Receiving TNF-α Inhibitor Therapy: Expanding the Groups at Risk. <i>Eur J Gastroenterol Hepatol</i>. 2011;23(12):1150-1156.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/21941193/pubmed" id="21941193" target="_blank">21941193</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24707412">
<a name="24707412"></a>Parekh R, Kaur N. Liver injury secondary to anti-TNF-alpha therapy in inflammatory bowel disease: a case series and review of the literature. <i>Case Rep Gastrointest Med</i>. 2014;2014:956463. doi:10.1155/2014/956463<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/24707412/pubmed" id="24707412" target="_blank">24707412</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19626656">
<a name="19626656"></a>Pentsuk N, van der Laan JW. An interspecies comparison of placental antibody transfer: new insights into developmental toxicity testing of monoclonal antibodies. <i>Birth Defects Res B Dev Reprod Toxicol</i>. 2009;86(4):328-344.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/19626656/pubmed" id="19626656" target="_blank">19626656</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28854831">
<a name="28854831"></a>Pérez-De-Lis M, Retamozo S, Flores-Chávez A, et al. Autoimmune diseases induced by biological agents. A review of 12,731 cases (BIOGEAS Registry). <i>Expert Opin Drug Saf</i>. 2017;16(11):1255-1271. doi:10.1080/14740338.2017.1372421<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/28854831/pubmed" id="28854831" target="_blank">28854831</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28110056">
<a name="28110056"></a>Picard M, Galvão VR. Current knowledge and management of hypersensitivity reactions to monoclonal antibodies. <i>J Allergy Clin Immunol Pract</i>. 2017;5(3):600-609. doi:10.1016/j.jaip.2016.12.001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/28110056/pubmed" id="28110056" target="_blank">28110056</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26235565">
<a name="26235565"></a>Pugliese D, Guidi L, Ferraro PM, et al. Paradoxical psoriasis in a large cohort of patients with inflammatory bowel disease receiving treatment with anti-TNF alpha: 5-year follow-up study. <i>Aliment Pharmacol Ther</i>. 2015;42(7):880-888. doi:10.1111/apt.13352<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/26235565/pubmed" id="26235565" target="_blank">26235565</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25107559">
<a name="25107559"></a>Raaschou P, Frisell T, Askling J; ARTIS Study Group. TNF inhibitor therapy and risk of breast cancer recurrence in patients with rheumatoid arthritis: a nationwide cohort study. <i>Ann Rheum Dis</i>. 2015;74(12):2137-2143. doi:10.1136/annrheumdis-2014-205745<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/25107559/pubmed" id="25107559" target="_blank">25107559</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28543445">
<a name="28543445"></a>Rademaker M, Agnew K, Andrews M, et al. Psoriasis in those planning a family, pregnant or breast-feeding. The Australasian Psoriasis Collaboration. <i>Australas J Dermatol</i>. 2018;59(2):86-100.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/28543445/pubmed" id="28543445" target="_blank">28543445</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29627896">
<a name="29627896"></a>Radovanović-Dinić B, Tešić-Rajković S, Zivkovic V, Grgov S. Clinical connection between rheumatoid arthritis and liver damage. <i>Rheumatol Int</i>. 2018;38(5):715-724. doi:10.1007/s00296-018-4021-5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/29627896/pubmed" id="29627896" target="_blank">29627896</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17632266">
<a name="17632266"></a>Ramos-Casals M, Brito-Zerón P, Muñoz S, et al. Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases. <i>Medicine (Baltimore)</i>. 2007;86(4):242-251. doi:10.1097/MD.0b013e3181441a68<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/17632266/pubmed" id="17632266" target="_blank">17632266</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19854301">
<a name="19854301"></a>Ramos-Casals M, Roberto-Perez-Alvarez, Diaz-Lagares C, Cuadrado MJ, Khamashta MA; BIOGEAS Study Group. Autoimmune diseases induced by biological agents: a double-edged sword? <i>Autoimmun Rev</i>. 2010;9(3):188-193. doi:10.1016/j.autrev.2009.10.003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/19854301/pubmed" id="19854301" target="_blank">19854301</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-manu.1">
<a name="manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12907338">
<a name="12907338"></a>Regueiro M, Valentine J, Plevy S, Fleisher MR, Lichtenstein GR. Infliximab for treatment of pyoderma gangrenosum associated with inflammatory bowel disease. <i>Am J Gastroenterol</i>. 2003;98(8):1821-1826.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/12907338/pubmed" id="12907338" target="_blank">12907338</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Remicade (infliximab) [prescribing information]. Horsham, PA: Janssen Biotech Inc; March 2020.</div>
</li>
<li>
<div class="reference">
                  Remicade (infliximab) [prescribing information]. Horsham, PA: Janssen Biotech Inc; October 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Remicade.1">
<a name="Remicade.1"></a>Remicade (infliximab) [product monograph]. Toronto, Ontario, Canada: Janssen Inc; October 2022.</div>
</li>
<li>
<div class="reference">
                  Remsima SC (infliximab) [product monograph]. Toronto, Ontario, Canada: Celltrion Healthcare Canada Limited; March 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Renflexis.1">
<a name="Renflexis.1"></a>Renflexis (infliximab-abda) [prescribing information]. Whitehouse Station, NJ: Merck Sharp &amp; Dohme Corp; January 2023.</div>
</li>
<li>
<div class="reference">
                  Renflexis (infliximab) [product monograph]. Kirkland, Quebec, Canada: Merck Canada Inc; February 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24339215">
<a name="24339215"></a>Ringold S, Weiss PF, Colbert RA, et al; Juvenile Idiopathic Arthritis Research Committee of the Childhood Arthritis and Rheumatology Research Alliance. Childhood Arthritis and Rheumatology Research Alliance consensus treatment plans for new-onset polyarticular juvenile idiopathic arthritis. <i>Arthritis Care Res (Hoboken)</i>. 2014;66(7):1063-1072. doi:10.1002/acr.22259<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/24339215/pubmed" id="24339215" target="_blank">24339215</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22609220">
<a name="22609220"></a>Robinson A, Van Voorhees AS, Hsu S, et al. Treatment of pustular psoriasis: from the Medical Board of the National Psoriasis Foundation. <i>J Am Acad Dermatol</i>. 2012;67(2):279-288.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/22609220/pubmed" id="22609220" target="_blank">22609220</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26140007">
<a name="26140007"></a>Rodrigues S, Lopes S, Magro F, et al. Autoimmune hepatitis and anti-tumor necrosis factor alpha therapy: a single center report of 8 cases. <i>World J Gastroenterol</i>. 2015;21(24):7584-7588. doi:10.3748/wjg.v21.i24.7584<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/26140007/pubmed" id="26140007" target="_blank">26140007</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24259964">
<a name="24259964"></a>Rojas-Feria M, Castro M, Suárez E, Ampuero J, Romero-Gómez M. Hepatobiliary manifestations in inflammatory bowel disease: the gut, the drugs and the liver. <i>World J Gastroenterol</i>. 2013;19(42):7327-7340. doi:10.3748/wjg.v19.i42.7327<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/24259964/pubmed" id="24259964" target="_blank">24259964</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33805757">
<a name="33805757"></a>Romanowska-Próchnicka K, Felis-Giemza A, Olesińska M, Wojdasiewicz P, Paradowska-Gorycka A, Szukiewicz D. The role of TNF-α and anti-TNF-α agents during preconception, pregnancy, and breastfeeding. <i>Int J Mol Sci</i>. 2021;22(6):2922. doi:10.3390/ijms22062922<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/33805757/pubmed" id="33805757" target="_blank">33805757</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25516646">
<a name="25516646"></a>Rossi RE, Parisi I, Despott EJ, et al. Anti-tumour necrosis factor agent and liver injury: literature review, recommendations for management. <i>World J Gastroenterol</i>. 2014;20(46):17352-1739. doi:10.3748/wjg.v20.i46.17352<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/25516646/pubmed" id="25516646" target="_blank">25516646</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30840605">
<a name="30840605"></a>Rubin DT, Ananthakrishnan AN, Siegel CA, Sauer BG, Long MD. ACG clinical guideline: ulcerative colitis in adults. <i>Am J Gastroenterol</i>. 2019;114(3):384-413. doi:10.14309/ajg.0000000000000152<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/30840605/pubmed" id="30840605" target="_blank">30840605</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15767026">
<a name="15767026"></a>Rubin RL. Drug-induced lupus. <i>Toxicology</i>. 2005;209(2):135-147. doi:10.1016/j.tox.2004.12.025<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/15767026/pubmed" id="15767026" target="_blank">15767026</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22516861">
<a name="22516861"></a>Rufo PA, Denson LA, Sylvester FA, et al. Health Supervision in the Management of Children and Adolescents With IBD: NASPGHAN Recommendations. <i>J Pediatr Gastroenterol Nutr</i>. 2012;55(1):93-108.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/22516861/pubmed" id="22516861" target="_blank">22516861</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17763439">
<a name="17763439"></a>Ruperto N, Lovell DJ, Cuttica R, et al. A Randomized, Placebo-Controlled Trial of Infliximab Plus Methotrexate for the Treatment of Polyarticular-Course Juvenile Rheumatoid Arthritis. <i>Arthritis Rheum</i>. 2007;56(9):3096-3106.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/17763439/pubmed" id="17763439" target="_blank">17763439</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20237125">
<a name="20237125"></a>Ruperto N, Lovell DJ, Cuttica R, et al. Paediatric Rheumatology INternational Trials Organization (PRINTO); Pediatric Rheumatology Collaborative Study Group (PRCSG). Long-term efficacy and safety of infliximab plus methotrexate for the treatment of polyarticular course juvenile rheumatoid arthritis: findings from an open-label treatment extension. <i>Ann Rheum Dis</i>. 2010;69(4):718-722.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/20237125/pubmed" id="20237125" target="_blank">20237125</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16339095">
<a name="16339095"></a>Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. <i>N Engl J Med</i>. 2005;353(23):2462-2476.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/16339095/pubmed" id="16339095" target="_blank">16339095</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15316423">
<a name="15316423"></a>Ryan BM, Romberg M, Wolters F, Stockbrugger RW. Extensive forearm deep venous thrombosis following a severe infliximab infusion reaction. <i>Eur J Gastroenterol Hepatol</i>. 2004;16(9):941-942. doi:10.1097/00042737-200409000-00022<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/15316423/pubmed" id="15316423" target="_blank">15316423</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35264154">
<a name="35264154"></a>Sakkat A, Cox G, Khalidi N, et al. Infliximab therapy in refractory sarcoidosis: a multicenter real-world analysis. <i>Respir Res.</i> 2022;23(1):54. doi:10.1186/s12931-022-01971-5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/35264154/pubmed" id="35264154" target="_blank">35264154</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29593717">
<a name="29593717"></a>Salomon BL, Leclerc M, Tosello J, Ronin E, Piaggio E, Cohen JL. Tumor necrosis factor α and regulatory T cells in oncoimmunology. <i>Front Immunol</i>. 2018;9:444. doi:10.3389/fimmu.2018.00444<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/29593717/pubmed" id="29593717" target="_blank">29593717</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32090480">
<a name="32090480"></a>Sammaritano LR, Bermas BL, Chakravarty EE, et al. 2020 American College of Rheumatology guideline for the management of reproductive health in rheumatic and musculoskeletal diseases. <i>Arthritis Rheumatol</i>. 2020;72(4):529-556. doi:10.1002/art.41191<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/32090480/pubmed" id="32090480" target="_blank">32090480</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16439435">
<a name="16439435"></a>Schiff MH, Burmester GR, Kent JD, et al. Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis. <i>Ann Rheum Dis</i>. 2006;65(7):889-894. doi:10.1136/ard.2005.043166<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/16439435/pubmed" id="16439435" target="_blank">16439435</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34724392">
<a name="34724392"></a>Schneider BJ, Naidoo J, Santomasso BD, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. <i>J Clin Oncol</i>. 2021;39(36):4073-4126. doi:10.1200/JCO.21.01440<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/34724392/pubmed" id="34724392" target="_blank">34724392</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26339470">
<a name="26339470"></a>Schrijvers R, Gilissen L, Chiriac AM, Demoly P. Pathogenesis and diagnosis of delayed-type drug hypersensitivity reactions, from bedside to bench and back. <i>Clin Transl Allergy</i>. 2015;5:31. doi:10.1186/s13601-015-0073-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/26339470/pubmed" id="26339470" target="_blank">26339470</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25169849">
<a name="25169849"></a>Sedger LM, McDermott MF. TNF and TNF-receptors: from mediators of cell death and inflammation to therapeutic giants - past, present and future. <i>Cytokine Growth Factor Rev</i>. 2014;25(4):453-472. doi:10.1016/j.cytogfr.2014.07.016<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/25169849/pubmed" id="25169849" target="_blank">25169849</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28976720">
<a name="28976720"></a>Senilă S, Seicean A, Fechete O, Grad A, Ungureanu L. Infliximab-induced acne and acute localized exanthematous pustulosis: case report. <i>Dermatol Ther</i>. 2017;30(6). doi:10.1111/dth.12554<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/28976720/pubmed" id="28976720" target="_blank">28976720</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32025603">
<a name="32025603"></a>Shah P, Sundaram V, Björnsson E. Biologic and checkpoint inhibitor-induced liver injury: a systematic literature review. <i>Hepatol Commun</i>. 2020;4(2):172-184. doi:10.1002/hep4.1465<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/32025603/pubmed" id="32025603" target="_blank">32025603</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7746084">
<a name="7746084"></a>Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. <i>Lancet</i>. 1995;345(8980):1312-1313.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/7746084/pubmed" id="7746084" target="_blank">7746084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25756190">
<a name="25756190"></a>Shelton E, Chaudrey K, Sauk J, et al. New onset idiosyncratic liver enzyme elevations with biological therapy in inflammatory bowel disease. <i>Aliment Pharmacol Ther</i>. 2015;41(10):972-979. doi:10.1111/apt.13159<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/25756190/pubmed" id="25756190" target="_blank">25756190</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11950005">
<a name="11950005"></a>Shergy WJ, Isern RA, Cooley DA, et al. Open Label Study to Assess Infliximab Safety and Timing of Onset of Clinical Benefit among Patients With Rheumatoid Arthritis. <i>J Rheumatol</i>. 2002;29(4):667-677.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/11950005/pubmed" id="11950005" target="_blank">11950005</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22886739">
<a name="22886739"></a>Simard JF, Neovius M, Askling J; ARTIS Study Group. Mortality rates in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors: drug-specific comparisons in the Swedish Biologics Register. <i>Arthritis Rheum</i>. 2012;64(11):3502-3510. doi:10.1002/art.34582<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/22886739/pubmed" id="22886739" target="_blank">22886739</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21328309">
<a name="21328309"></a>Singh JA, Wells GA, Christensen R, et al. Adverse effects of biologics: a network meta-analysis and Cochrane overview. <i>Cochrane Database Syst Rev</i>. 2011;2011(2):CD008794. doi:10.1002/14651858.CD008794.pub2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/21328309/pubmed" id="21328309" target="_blank">21328309</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30876964">
<a name="30876964"></a>Singh S, Facciorusso A, Dulai PS, Jairath V, Sandborn WJ. Comparative risk of serious infections with biologic and/or immunosuppressive therapy in patients with inflammatory bowel diseases: a systematic review and meta-analysis. <i>Clin Gastroenterol Hepatol</i>. 2020;18(1):69-81.e3. doi:10.1016/j.cgh.2019.02.044<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/30876964/pubmed" id="30876964" target="_blank">30876964</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23680215">
<a name="23680215"></a>Smith N, Harms KL, Hines AC, et al. Acute treatment of generalized pustular psoriasis of von Zumbusch with single-dose infliximab. <i>J Am Acad Dermatol</i>. 2013;68(6):e187-e189.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/23680215/pubmed" id="23680215" target="_blank">23680215</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25776112">
<a name="25776112"></a>Solomon DH, Reed GW, Kremer JM, et al. Disease activity in rheumatoid arthritis and the risk of cardiovascular events. <i>Arthritis Rheumatol</i>. 2015;67(6):1449-1455. doi:10.1002/art.39098<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/25776112/pubmed" id="25776112" target="_blank">25776112</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21129756">
<a name="21129756"></a>Son MB, Gauvreau K, Burns JC, et al. Infliximab for intravenous immunoglobulin resistance in Kawasaki disease: a retrospective study. <i>J Pediatr</i>. 2011;158(4):644-649.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/21129756/pubmed" id="21129756" target="_blank">21129756</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29718343">
<a name="29718343"></a>Sridhar S, Maltz RM, Boyle B, Kim SC. Dermatological manifestations in pediatric patients with inflammatory bowel diseases on anti-TNF therapy. <i>Inflamm Bowel Dis</i>. 2018;24(9):2086-2092. doi:10.1093/ibd/izy112<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/29718343/pubmed" id="29718343" target="_blank">29718343</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21535447">
<a name="21535447"></a>Steenholdt C, Svenson M, Bendtzen K, Thomsen OØ, Brynskov J, Ainsworth MA. Severe infusion reactions to infliximab: aetiology, immunogenicity and risk factors in patients with inflammatory bowel disease. <i>Aliment Pharmacol Ther</i>. 2011;34(1):51-58. doi:10.1111/j.1365-2036.2011.04682.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/21535447/pubmed" id="21535447" target="_blank">21535447</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18494064">
<a name="18494064"></a>Stengel JZ, Arnold HL. Is infliximab safe to use while breastfeeding? <i>World J Gastroenterol</i>. 2008;14(19):3085-3087.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/18494064/pubmed" id="18494064" target="_blank">18494064</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12526944">
<a name="12526944"></a>Stephens MC, Shepanski MA, Mamula P, Markowitz JE, Brown KA, Baldassano RN. Safety and steroid-sparing experience using infliximab for Crohn's disease at a pediatric inflammatory bowel disease center. <i>Am J Gastroenterol</i>. 2003;98(1):104-111. doi:10.1111/j.1572-0241.2003.07161.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/12526944/pubmed" id="12526944" target="_blank">12526944</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21791449">
<a name="21791449"></a>Strangfeld A, Eveslage M, Schneider M, et al. Treatment benefit or survival of the fittest: what drives the time-dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient? <i>Ann Rheum Dis</i>. 2011;70(11):1914-1920. doi:10.1136/ard.2011.151043<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/21791449/pubmed" id="21791449" target="_blank">21791449</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20064207">
<a name="20064207"></a>Strangfeld A, Hierse F, Rau R, et al. Risk of incident or recurrent malignancies among patients with rheumatoid arthritis exposed to biologic therapy in the German biologics register RABBIT. <i>Arthritis Res Ther</i>. 2010;12(1):R5. doi:10.1186/ar2904<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/20064207/pubmed" id="20064207" target="_blank">20064207</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24910924">
<a name="24910924"></a>Sugiura K, Endo K, Akasaka T, Akiyama M. Successful treatment with infliximab of sibling cases with generalized pustular psoriasis caused by deficiency of interleukin-36 receptor antagonist. <i>J Eur Acad Dermatol Venereol</i>. 2015;29(10):2054-2056. doi:10.1111/jdv.12590<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/24910924/pubmed" id="24910924" target="_blank">24910924</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35690919">
<a name="35690919"></a>Szczepanik A, Choi D, Brady B, et al. The use of non-transplant biologics in solid organ transplant recipients: a practical review for the frontline clinician. <i>Clin Transplant</i>. 2022;36(7):e14743. doi:10.1111/ctr.14743<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/35690919/pubmed" id="35690919" target="_blank">35690919</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34300342">
<a name="34300342"></a>Szymanska E, Dadalski M, Sieczkowska-Golub J, et al. Premedication does not influence the incidence of infliximab infusion reactions in pediatric patients with inflammatory bowel disease-a single center case-control study. <i>J Clin Med</i>. 2021;10(14):3177. doi:10.3390/jcm10143177<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/34300342/pubmed" id="34300342" target="_blank">34300342</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23950184">
<a name="23950184"></a>Tambralli A, Beukelman T, Weiser P, Atkinson TP, Cron RQ, Stoll ML. High doses of infliximab in the management of juvenile idiopathic arthritis. <i>J Rheumatol</i>. 2013;40(10):1749-1755 doi:10.3899/jrheum.130133<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/23950184/pubmed" id="23950184" target="_blank">23950184</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33863839">
<a name="33863839"></a>Taylor TRP, Galloway J, Davies R, Hyrich K, Dobson R. Demyelinating events following initiation of anti-TNFα therapy in the British Society for Rheumatology Biologics Registry in Rheumatoid Arthritis. <i>Neurol Neuroimmunol Neuroinflamm</i>. 2021;8(3):e992. doi:10.1212/NXI.0000000000000992<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/33863839/pubmed" id="33863839" target="_blank">33863839</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24267474">
<a name="24267474"></a>Terdiman JP, Gruss CB, Heidelbaugh JJ, et al. American Gastroenterological Association Institute guideline on the use of thiopurines, methotrexate, and anti-TNF-α biologic drugs for the induction and maintenance of remission in inflammatory Crohn's disease. <i>Gastroenterology</i>. 2013;145(6):1459-1463.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/24267474/pubmed" id="24267474" target="_blank">24267474</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29405329">
<a name="29405329"></a>Terrault NA, Lok ASF, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. <i>Hepatology</i>. 2018;67(4):1560-1599. doi:10.1002/hep.29800<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/29405329/pubmed" id="29405329" target="_blank">29405329</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21544940">
<a name="21544940"></a>Torii H, Nakagawa H; Japanese Infliximab Study Investigators. Long-term study of infliximab in Japanese patients with plaque psoriasis, psoriatic arthritis, pustular psoriasis and psoriatic erythroderma. <i>J Dermatol</i>. 2011;38(4):321-334.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/21544940/pubmed" id="21544940" target="_blank">21544940</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21839501">
<a name="21839501"></a>Torres MJ, Chaves P, Doña I, et al. T-cell involvement in delayed-type hypersensitivity reactions to infliximab. <i>J Allergy Clin Immunol</i>. 2011;128(6):1365-1367.e1. doi:10.1016/j.jaci.2011.06.050<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/21839501/pubmed" id="21839501" target="_blank">21839501</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24572997">
<a name="24572997"></a>Tremoulet AH, Jain S, Jaggi P, et al. Infliximab for intensification of primary therapy for Kawasaki disease: a phase 3 randomised, double-blind, placebo-controlled trial. <i>Lancet</i>. 2014;383(9930):1731-1738. doi:10.1016/S0140-6736(13)62298-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/24572997/pubmed" id="24572997" target="_blank">24572997</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16091999">
<a name="16091999"></a>Trent JT, Kerdel FA. Successful treatment of Von Zumbusch pustular psoriasis with infliximab. <i>J Cutan Med Surg</i>. 2004;8(4):224-228.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/16091999/pubmed" id="16091999" target="_blank">16091999</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30044357">
<a name="30044357"></a>Turner D, Ruemmele FM, Orlanski-Meyer E, et al. Management of paediatric ulcerative colitis, part 1: ambulatory care-an evidence-based guideline from European Crohn's and Colitis Organization and European Society of Paediatric Gastroenterology, Hepatology and Nutrition. <i>J Pediatr Gastroenterol Nutr</i>. 2018a;67(2):257-291. doi:10.1097/MPG.0000000000002035<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/30044357/pubmed" id="30044357" target="_blank">30044357</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30044358">
<a name="30044358"></a>Turner D, Ruemmele FM, Orlanski-Meyer E, et al. Management of paediatric ulcerative colitis, part 2: acute severe colitis-an evidence-based consensus guideline from the European Crohn's and Colitis Organization and the European Society of Paediatric Gastroenterology, Hepatology and Nutrition. <i>J Pediatr Gastroenterol Nutr</i>. 2018b;67(2):292-310. doi:10.1097/MPG.0000000000002036<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/30044358/pubmed" id="30044358" target="_blank">30044358</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21623000">
<a name="21623000"></a>Tynjälä P, Vähäsalo P, Tarkiainen M, et al. Aggressive combination drug therapy in very early polyarticular juvenile idiopathic arthritis (ACUTE-JIA): a multicentre randomised open-label clinical trial. <i>Ann Rheum Dis</i>. 2011;70(9):1605-1612. doi:10.1136/ard.2010.143347<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/21623000/pubmed" id="21623000" target="_blank">21623000</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33026087">
<a name="33026087"></a>van Rheenen PF, Aloi M, Assa A, et al. The medical management of paediatric Crohn's disease: an ECCO-ESPGHAN guideline update. <i>J Crohns Colitis</i>. Published online October 7, 2020. doi:10.1093/ecco-jcc/jjaa161<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/33026087/pubmed" id="33026087" target="_blank">33026087</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31332475">
<a name="31332475"></a>van Wassenaer EA, Meester VL, Kindermann A, Koot BGP, Benninga MA, de Meij TGJ. Premedication with intravenous steroids does not influence the incidence of infusion reactions following infliximab infusions in pediatric inflammatory bowel disease patients-a case-control study. <i>Eur J Clin Pharmacol</i>. 2019;75(10):1445-1450. doi:10.1007/s00228-019-02715-z<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/31332475/pubmed" id="31332475" target="_blank">31332475</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17045211">
<a name="17045211"></a>Vasiliauskas EA, Church JA, Silverman N, Barry M, Targan SR, Dubinsky MC. Case report: evidence for transplacental transfer of maternally administered infliximab to the newborn. <i>Clin Gastroenterol Hepatol</i>. 2006;4(10):1255-1258.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/17045211/pubmed" id="17045211" target="_blank">17045211</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12851868">
<a name="12851868"></a>Vermeire S, Noman M, Van Assche G, et al. Autoimmunity associated with anti-tumor necrosis factor alpha treatment in Crohn's disease: a prospective cohort study. <i>Gastroenterology</i>. 2003;125(1):32-39. doi:10.1016/s0016-5085(03)00701-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/12851868/pubmed" id="12851868" target="_blank">12851868</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23247492">
<a name="23247492"></a>Viguier M, Aubin F, Delaporte E, et al; Groupe de Recherche sur le Psoriasis de la Société Française de Dermatologie. Efficacy and safety of tumor necrosis factor inhibitors in acute generalized pustular psoriasis. <i>Arch Dermatol</i>. 2012;148(12):1423-1425.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/23247492/pubmed" id="23247492" target="_blank">23247492</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20822542">
<a name="20822542"></a>Visvanathan S, Wagner C, Marini JC, et al; Paediatric Rheumatology INternational Trials Organization (PRINTO); Pediatric Rheumatology Collaborative Study Group (PRCSG). The effect of infliximab plus methotrexate on the modulation of inflammatory disease markers in juvenile idiopathic arthritis: analyses from a randomized, placebo-controlled trial. <i>Pediatr Rheumatol Online J</i>. 2010;8:24.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/20822542/pubmed" id="20822542" target="_blank">20822542</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9826720">
<a name="9826720"></a>Wagner UG, Koetz K, Weyand CM, Goronzy JJ. Perturbation of the T cell repertoire in rheumatoid arthritis. <i>Proc Natl Acad Sci U S A</i>. 1998;95(24):14447-14452. doi:10.1073/pnas.95.24.14447<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/9826720/pubmed" id="9826720" target="_blank">9826720</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34319562">
<a name="34319562"></a>Waldron JL, Schworer SA, Kwan M. Hypersensitivity and immune-related adverse events in biologic therapy. <i>Clin Rev Allergy Immunol</i>. 2022;62(3):413-431. doi:10.1007/s12016-021-08879-w<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/34319562/pubmed" id="34319562" target="_blank">34319562</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36402978">
<a name="36402978"></a>Wang H, Hu Y, Chen F, Shen M. Comparative safety of infliximab and adalimumab on pregnancy outcomes of women with inflammatory bowel diseases: a systematic review and meta-analysis. <i>BMC Pregnancy Childbirth</i>. 2022;22(1):854. doi:10.1186/s12884-022-05191-z<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/36402978/pubmed" id="36402978" target="_blank">36402978</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15088313">
<a name="15088313"></a>Weiss JE, Eberhard BA, Chowdhury D, Gottlieb BS. Infliximab as a novel therapy for refractory Kawasaki disease. <i>J Rheumatol</i>. 2004;31(4):808-810.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/15088313/pubmed" id="15088313" target="_blank">15088313</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30346529">
<a name="30346529"></a>Weizman AV, Nguyen GC, Seow CH, et al. Appropriateness of biologics in the management of Crohn's disease using RAND/UCLA appropriateness methodology. <i>Inflamm Bowel Dis</i>. 2019;25(2):328-335.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/30346529/pubmed" id="30346529" target="_blank">30346529</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35745812">
<a name="35745812"></a>Wiersma TK, Visschedijk MC, de Boer NK, et al. The effect of pregnancy and inflammatory bowel disease on the pharmacokinetics of drugs related to inflammatory bowel disease-a systematic literature review. <i>Pharmaceutics</i>. 2022;14(6):1241. doi:10.3390/pharmaceutics14061241<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/35745812/pubmed" id="35745812" target="_blank">35745812</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32443029">
<a name="32443029"></a>Winter DA, Joosse ME, de Wildt SN, Taminiau J, de Ridder L, Escher JC. Pharmacokinetics, pharmacodynamics, and immunogenicity of infliximab in pediatric inflammatory bowel disease: a systematic review and revised dosing considerations. <i>J Pediatr Gastroenterol Nutr</i>. 2020;70(6):763-776. doi:10.1097/MPG.0000000000002631<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/32443029/pubmed" id="32443029" target="_blank">32443029</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16447241">
<a name="16447241"></a>Wolfe F, Caplan L, Michaud K. Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia: associations with prednisone, disease-modifying antirheumatic drugs, and anti-tumor necrosis factor therapy. <i>Arthritis Rheum</i>. 2006;54(2):628-634. doi:10.1002/art.21568<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/16447241/pubmed" id="16447241" target="_blank">16447241</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32127737">
<a name="32127737"></a>Worland T, Chin KL, van Langenberg D, Garg M, Nicoll A. Retrospective study of idiosyncratic drug-induced liver injury from infliximab in an inflammatory bowel disease cohort: the IDLE study. Ann <i>Gastroenterol</i>. 2020;33(2):162-169. doi:10.20524/aog.2020.0453<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/32127737/pubmed" id="32127737" target="_blank">32127737</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24185311">
<a name="24185311"></a>Yanai H, Shuster D, Calabrese E, Mlynarsky L, Tumuluri S, Cohen RD. The incidence and predictors of lupus-like reaction in patients with IBD treated with anti-TNF therapies. <i>Inflamm Bowel Dis</i>. 2013;19(13):2778-2786. doi:10.1097/01.MIB.0000435435.91988.b6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/24185311/pubmed" id="24185311" target="_blank">24185311</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26673981">
<a name="26673981"></a>Youn Y, Kim J, Hong YM, Sohn S. Infliximab as the first retreatment in patients with Kawasaki Disease resistant to initial intravenous immunoglobulin. <i>Pediatr Infect Dis J</i>. 2016;35(4):457-459.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/26673981/pubmed" id="26673981" target="_blank">26673981</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24608404">
<a name="24608404"></a>Yun H, Xie F, Delzell E, Chen L, et al. Risk of hospitalised infection in rheumatoid arthritis patients receiving biologics following a previous infection while on treatment with anti-TNF therapy. <i>Ann Rheum Dis</i>. 2015;74(6):1065-1071. doi:10.1136/annrheumdis-2013-204011<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/24608404/pubmed" id="24608404" target="_blank">24608404</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34789551">
<a name="34789551"></a>Zou F, Faleck D, Thomas A, et al. Efficacy and safety of vedolizumab and infliximab treatment for immune-mediated diarrhea and colitis in patients with cancer: a two-center observational study. <i>J Immunother Cancer</i>. 2021;9(11):e003277. doi:10.1136/jitc-2021-003277<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/infliximab-including-biosimilars-pediatric-drug-information/abstract-text/34789551/pubmed" id="34789551" target="_blank">34789551</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 13381 Version 353.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
